[
  {
    "chunk_id": "402a36df_0000",
    "doc_id": "402a36df",
    "filename": "amoxicillin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "AMOXICILLIN - Complete Medication Guide",
    "drug_name": "Amoxicillin",
    "chunk_index": 0,
    "text": "AMOXICILLIN - Complete Medication Guide\n\nGENERIC NAME: Amoxicillin\nBRAND NAMES: Amoxil, Moxatag, Trimox\n\nDRUG CLASS: Penicillin Antibiotic (Aminopenicillin)\n\nMECHANISM OF ACTION:\nAmoxicillin is a bactericidal antibiotic that works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) inside the bacterial cell wall, inhibiting the transpeptidation step of peptidoglycan synthesis. This weakens the cell wall and leads to osmotic lysis and death of susceptible bacteria. Amoxicillin is effective against gram-positive and some gram-negative bacteria.\n\nINDICATIONS AND USAGE:\n- Upper respiratory infections: Pharyngitis, tonsillitis, sinusitis, otitis media\n- Lower respiratory infections: Bronchitis, pneumonia\n- Skin and skin structure infections\n- Urinary tract infections (UTI)\n- Helicobacter pylori eradication (with other medications)\n- Lyme disease (early stages)\n- Prophylaxis for bacterial endocarditis (dental procedures)\n- Anthrax exposure (post-exposure prophylaxis)\n\nCOMMON BACTERIA COVERED:\n- Streptococcus pneumoniae\n- Streptococcus pyogenes\n- Haemophilus influenzae\n- Escherichia coli\n- Proteus mirabilis\n- Salmonella species\n- Enterococcus faecalis\n- Helicobacter pylori\n\nDOSAGE GUIDELINES:\nAdults:\n- Mild to moderate infections: 250-500 mg every 8 hours\n- Severe infections: 875 mg every 12 hours\n- Maximum dose: 2-3 grams per day\n\nChildren (based on weight):\n- 20-40 mg/kg/day in divided doses every 8 hours\n- 25-45 mg/kg/day in divided doses every 12 hours\n- Maximum: 2-3 grams per day\n\nSpecial populations:\n- Renal impairment: Dose adjustment required for CrCl <30 mL/min\n- Hemodialysis: Administer after dialysis\n- Elderly: Use normal adult dosing unless renal impairment\n\nCONTRAINDICATIONS:\n- Known hypersensitivity to penicillins or beta-lactam antibiotics\n- History of severe allergic reaction to cephalosporins (cross-sensitivity)\n- Infectious mononucleosis (increased risk of rash)\n\nWARNINGS AND PRECAUTIONS:\n- Anaphylaxis: Serious allergic reactions can occur (0.01-0.05% of courses)\n- Cross-sensitivity: 10% cross-sensitivity with cephalosporins\n- Clostridium difficile-associated diarrhea: Can occur during or after treatment\n- Superinfection: Prolonged use may cause fungal or bacterial overgrowth\n- Jarisch-Herxheimer reaction: In treatment of Lyme disease or syphilis\n- False-positive urine glucose tests (copper reduction method)\n\nCOMMON SIDE EFFECTS:\n- Diarrhea (most common, 5-10%)\n- Nausea and vomiting\n- Abdominal pain\n- Rash (especially in patients with mononucleosis)\n- Vaginal yeast infection\n- Headache\n- Altered taste",
    "word_count": 351,
    "metadata": {
      "doc_id": "402a36df",
      "filename": "amoxicillin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "AMOXICILLIN - Complete Medication Guide",
      "drug_name": "Amoxicillin",
      "source": "medical_document",
      "word_count": 702,
      "char_count": 5180
    }
  },
  {
    "chunk_id": "402a36df_0001",
    "doc_id": "402a36df",
    "filename": "amoxicillin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "AMOXICILLIN - Complete Medication Guide",
    "drug_name": "Amoxicillin",
    "chunk_index": 1,
    "text": "SERIOUS SIDE EFFECTS (seek medical attention):\n- Severe allergic reaction (anaphylaxis): difficulty breathing, hives, swelling\n- Clostridium difficile diarrhea: watery/bloody diarrhea, abdominal cramping\n- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis\n- Seizures (especially with high doses or renal impairment)\n- Hepatitis or cholestatic jaundice (rare)\n- Interstitial nephritis (rare)\n\nDRUG INTERACTIONS:\n1. Probenecid: Increases amoxicillin levels (used intentionally)\n2. Methotrexate: Decreased methotrexate elimination, increased toxicity\n3. Oral contraceptives: Possibly reduced contraceptive efficacy (use backup method)\n4. Allopurinol: Increased risk of rash\n5. Warfarin: May increase INR (monitor closely)\n6. Typhoid vaccine: Reduced vaccine efficacy\n7. Tetracyclines: May interfere with bactericidal action\n\nPREGNANCY AND LACTATION:\n- Pregnancy Category B: Generally considered safe\n- Crosses placenta but no evidence of fetal harm\n- Excreted in breast milk in small amounts\n- Generally compatible with breastfeeding (may cause diarrhea in infant)\n\nPHARMACOKINETICS:\n- Absorption: Rapidly and well absorbed (75-90% bioavailability)\n- Food effect: Not significantly affected by food\n- Peak levels: 1-2 hours after oral dose\n- Distribution: Widely distributed; crosses placental barrier\n- Protein binding: 17-20%\n- Metabolism: Partial hepatic metabolism\n- Half-life: 60-90 minutes (prolonged in renal impairment)\n- Excretion: 60-80% excreted unchanged in urine\n\nSPECTRUM OF ACTIVITY:\nGood activity against:\n- Streptococcus species\n- Enterococcus faecalis\n- Listeria monocytogenes\n- E. coli (non-ESBL producing)\n- Proteus mirabilis\n- Salmonella species\n- Helicobacter pylori\n\nLimited activity (resistance common):\n- Staphylococcus aureus (many strains resistant)\n- Klebsiella species\n- Pseudomonas aeruginosa\n- Anaerobes (better coverage with ampicillin-sulbactam)\n\nRESISTANCE MECHANISMS:\n- Beta-lactamase production (most common)\n- Altered penicillin-binding proteins\n- Reduced permeability\n- Efflux pumps\n\nSTORAGE:\n- Store at room temperature 20-25°C (68-77°F)\n- Keep away from moisture and heat\n- Oral suspension: Refrigerate after reconstitution, discard after 14 days\n- Protect from light\n\nPATIENT EDUCATION:\n- Take at evenly spaced intervals to maintain blood levels\n- Complete entire course even if feeling better\n- Do not share antibiotics with others\n- Report any rash or signs of allergic reaction\n- Use alternative contraception if on birth control pills\n- Probiotics may help prevent diarrhea\n- Shake oral suspension well before use",
    "word_count": 351,
    "metadata": {
      "doc_id": "402a36df",
      "filename": "amoxicillin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "AMOXICILLIN - Complete Medication Guide",
      "drug_name": "Amoxicillin",
      "source": "medical_document",
      "word_count": 702,
      "char_count": 5180
    }
  },
  {
    "chunk_id": "b814d355_0000",
    "doc_id": "b814d355",
    "filename": "ibuprofen.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "IBUPROFEN - Complete Medication Guide",
    "drug_name": "Ibuprofen",
    "chunk_index": 0,
    "text": "IBUPROFEN - Complete Medication Guide\n\nGENERIC NAME: Ibuprofen\nBRAND NAMES: Advil, Motrin, Nurofen, Caldolor\n\nDRUG CLASS: Nonsteroidal Anti-inflammatory Drug (NSAID)\n\nMECHANISM OF ACTION:\nIbuprofen works by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). These enzymes are responsible for producing prostaglandins, which are chemical messengers that cause inflammation, pain, and fever in the body. By blocking these enzymes, ibuprofen reduces the production of prostaglandins, leading to decreased pain and inflammation.\n\nINDICATIONS AND USAGE:\n- Mild to moderate pain relief (headache, toothache, backache)\n- Fever reduction\n- Inflammation reduction (arthritis, muscle strains)\n- Menstrual cramps (dysmenorrhea)\n- Minor aches and pains\n\nDOSAGE GUIDELINES:\nAdults and children over 12 years:\n- 200-400mg every 4-6 hours as needed\n- Do not exceed 1200mg per day without doctor supervision\n- Take with food or milk to reduce stomach upset\n\nChildren (under 12):\n- Weight-based dosing: 5-10mg/kg every 6-8 hours\n- Maximum: 40mg/kg per day\n\nCONTRAINDICATIONS:\n- Known hypersensitivity to ibuprofen or other NSAIDs\n- History of asthma attacks after taking NSAIDs\n- Active peptic ulcer disease or GI bleeding\n- Severe heart failure (NYHA class III-IV)\n- Late pregnancy (third trimester, can cause premature closure of ductus arteriosus)\n- Coronary artery bypass graft (CABG) surgery perioperative pain\n\nWARNINGS AND PRECAUTIONS:\n- Cardiovascular risk: May increase risk of serious cardiovascular thrombotic events\n- Gastrointestinal risk: Can cause GI bleeding, ulceration, and perforation\n- Renal effects: Can reduce renal blood flow, risk in elderly or dehydrated patients\n- Hepatic effects: Rare cases of severe liver injury\n- Anaphylactoid reactions: Can occur in patients with aspirin triad\n\nCOMMON SIDE EFFECTS:\n- Nausea and vomiting\n- Heartburn and dyspepsia\n- Diarrhea or constipation\n- Dizziness and headache\n- Drowsiness\n\nSERIOUS SIDE EFFECTS (seek medical attention):\n- Signs of stomach bleeding: black/bloody stools, coffee-ground vomit\n- Signs of heart attack: chest pain, shortness of breath\n- Signs of stroke: sudden numbness, confusion, vision changes\n- Signs of allergic reaction: rash, hives, difficulty breathing\n- Signs of liver problems: dark urine, yellowing skin/eyes",
    "word_count": 333,
    "metadata": {
      "doc_id": "b814d355",
      "filename": "ibuprofen.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "IBUPROFEN - Complete Medication Guide",
      "drug_name": "Ibuprofen",
      "source": "medical_document",
      "word_count": 468,
      "char_count": 3271
    }
  },
  {
    "chunk_id": "b814d355_0001",
    "doc_id": "b814d355",
    "filename": "ibuprofen.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "IBUPROFEN - Complete Medication Guide",
    "drug_name": "Ibuprofen",
    "chunk_index": 1,
    "text": "DRUG INTERACTIONS:\n1. Warfarin (Coumadin): SEVERE - Increased bleeding risk\n2. Aspirin: MODERATE - Increased GI side effects, reduced cardioprotection\n3. Lisinopril (ACE inhibitors): MODERATE - Reduced blood pressure effect\n4. Metformin: MODERATE - Possible increased metformin levels\n5. Furosemide (diuretics): MODERATE - Reduced diuretic effect\n6. Lithium: MODERATE - Increased lithium levels, risk of toxicity\n7. Methotrexate: MODERATE - Increased methotrexate toxicity\n8. SSRIs (antidepressants): MILD - Increased bleeding risk\n\nPHARMACOKINETICS:\n- Absorption: Well absorbed orally (80-85% bioavailability)\n- Onset of action: 30-60 minutes\n- Peak plasma levels: 1-2 hours\n- Protein binding: 90-99% bound to plasma proteins\n- Metabolism: Hepatic via CYP2C9\n- Half-life: 2-4 hours\n- Excretion: Urine (primarily as metabolites, <1% unchanged)\n\nSTORAGE:\n- Store at room temperature 20-25°C (68-77°F)\n- Keep away from moisture and heat\n- Protect from light",
    "word_count": 135,
    "metadata": {
      "doc_id": "b814d355",
      "filename": "ibuprofen.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "IBUPROFEN - Complete Medication Guide",
      "drug_name": "Ibuprofen",
      "source": "medical_document",
      "word_count": 468,
      "char_count": 3271
    }
  },
  {
    "chunk_id": "0ad3d062_0000",
    "doc_id": "0ad3d062",
    "filename": "warfarin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "WARFARIN - Complete Medication Guide",
    "drug_name": "Warfarin",
    "chunk_index": 0,
    "text": "WARFARIN - Complete Medication Guide\n\nGENERIC NAME: Warfarin\nBRAND NAMES: Coumadin, Jantoven\n\nDRUG CLASS: Anticoagulant (Vitamin K Antagonist)\n\nMECHANISM OF ACTION:\nWarfarin inhibits the enzyme vitamin K epoxide reductase. This enzyme is responsible for recycling vitamin K, which is essential for the synthesis of clotting factors II, VII, IX, and X in the liver. By blocking this enzyme, warfarin reduces the production of these clotting factors, leading to a decreased ability for blood to clot. The full anticoagulant effect takes 3-5 days because existing clotting factors must naturally degrade.\n\nINDICATIONS AND USAGE:\n- Prophylaxis and treatment of venous thrombosis (deep vein thrombosis, DVT)\n- Prophylaxis and treatment of pulmonary embolism (PE)\n- Prevention of thromboembolic events in atrial fibrillation\n- Prevention of thromboembolic events after heart valve replacement\n- Reduction of risk of recurrent myocardial infarction\n- Prevention of stroke in patients with mechanical heart valves\n\nDOSAGE GUIDELINES:\n- Initial dose: 2-5 mg daily (based on patient factors)\n- Maintenance dose: 2-10 mg daily (individualized based on INR)\n- Dose adjustments based on International Normalized Ratio (INR)\n- Target INR depends on indication:\n  * Most indications: 2.0-3.0\n  * Mechanical heart valves: 2.5-3.5\n- Take at same time each day (usually evening)\n\nCONTRAINDICATIONS:\n- Active bleeding or hemorrhagic tendencies\n- Pregnancy (warfarin embryopathy, especially first trimester)\n- Recent or upcoming surgery (including dental surgery)\n- Severe uncontrolled hypertension\n- Pericarditis or pericardial effusion\n- Lumbar puncture or regional anesthesia\n- Inability to comply with monitoring requirements\n\nWARNINGS AND PRECAUTIONS:\n- Bleeding risk: Most serious adverse effect\n- Monitoring: Regular INR testing required (initially weekly, then monthly)\n- Dietary consistency: Vitamin K intake should be consistent\n- Drug interactions: Hundreds of drugs interact with warfarin\n- Genetic factors: CYP2C9 and VKORC1 variants affect metabolism\n- \"Warfarin necrosis\": Rare skin necrosis complication\n\nCOMMON SIDE EFFECTS:\n- Bleeding (epistaxis, gum bleeding, easy bruising)\n- Purplish toes (cholesterol microembolization)\n- Hair loss (reversible)\n- Skin rash\n- Nausea and vomiting\n- Abdominal pain\n\nSERIOUS SIDE EFFECTS (seek immediate medical attention):\n- Severe bleeding (internal, intracranial)\n- Signs of bleeding: black stools, blood in urine, coffee-ground vomit\n- Sudden severe headache (possible intracranial bleed)\n- Unexplained bruising or swelling\n- Warfarin-induced skin necrosis\n- Purple toe syndrome",
    "word_count": 371,
    "metadata": {
      "doc_id": "0ad3d062",
      "filename": "warfarin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "WARFARIN - Complete Medication Guide",
      "drug_name": "Warfarin",
      "source": "medical_document",
      "word_count": 696,
      "char_count": 4954
    }
  },
  {
    "chunk_id": "0ad3d062_0001",
    "doc_id": "0ad3d062",
    "filename": "warfarin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "WARFARIN - Complete Medication Guide",
    "drug_name": "Warfarin",
    "chunk_index": 1,
    "text": "DRUG INTERACTIONS (SIGNIFICANT):\nSEVERE INTERACTIONS:\n1. Ibuprofen and other NSAIDs: Increased bleeding risk\n2. Aspirin: Significantly increased bleeding risk\n3. Amiodarone: Increased warfarin effect (monitor INR closely)\n4. Fluconazole (antifungals): Increased warfarin effect\n5. Metronidazole: Increased warfarin effect\n6. Trimethoprim-sulfamethoxazole: Increased warfarin effect\n\nMODERATE INTERACTIONS:\n1. Acetaminophen (high doses, regular use): Increased INR\n2. Amoxicillin: Increased warfarin effect (disrupts gut flora)\n3. Ciprofloxacin: Increased warfarin effect\n4. Omeprazole: Possible increased warfarin effect\n5. Simvastatin: Possible increased warfarin effect\n6. Phenytoin: Complex bidirectional interaction\n7. Alcohol (chronic heavy use): Variable effects\n\nINTERACTIONS THAT DECREASE WARFARIN EFFECT:\n1. Vitamin K (dietary supplements)\n2. Rifampin\n3. Barbiturates\n4. Carbamazepine\n5. Cholestyramine\n6. Oral contraceptives\n\nDIETARY CONSIDERATIONS:\n- Consistent vitamin K intake is crucial\n- Vitamin K rich foods: leafy greens (kale, spinach, broccoli, Brussels sprouts)\n- Do not eliminate these foods, but keep intake consistent\n- Avoid cranberry juice (may increase warfarin effect)\n- Avoid alcohol (especially binge drinking)\n- Avoid herbal supplements: St. John's wort, ginseng, ginkgo, coenzyme Q10\n\nPHARMACOKINETICS:\n- Absorption: Rapid and complete oral absorption\n- Bioavailability: >95%\n- Protein binding: 99% bound to albumin\n- Metabolism: Hepatic via CYP2C9\n- Half-life: 20-60 hours (average 40 hours)\n- Onset of action: 24-72 hours\n- Duration of action: 2-5 days\n- Monitoring: INR (International Normalized Ratio)\n\nLABORATORY MONITORING:\n- INR target: Individualized (typically 2-3)\n- Frequency: Initially daily to weekly, then every 4 weeks when stable\n- Check INR before any surgical procedure\n- Pregnancy: Warfarin contraindicated (heparin used instead)\n\nPATIENT EDUCATION POINTS:\n- Take exactly as prescribed at same time daily\n- Missed dose: Take if remembered same day, otherwise skip\n- Never double up doses\n- Report any unusual bleeding or bruising\n- Use soft toothbrush and electric razor\n- Avoid contact sports\n- Carry medical alert identification\n- Inform all healthcare providers of warfarin use\n- Keep all appointments for INR testing\n- Do not start or stop any medication without consulting prescriber",
    "word_count": 325,
    "metadata": {
      "doc_id": "0ad3d062",
      "filename": "warfarin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "WARFARIN - Complete Medication Guide",
      "drug_name": "Warfarin",
      "source": "medical_document",
      "word_count": 696,
      "char_count": 4954
    }
  },
  {
    "chunk_id": "dcb90cee_0000",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 0,
    "text": "Pharmacotherapy \nHandbook\nNinth Edition\n\nNOTICE\nMedicine is an ever-changing science. As new research and clinical experience \nbroaden our knowledge, changes in treatment and drug therapy are required. \nThe authors of this work have checked with sources believed to be reliable in \ntheir efforts to provide information that is complete and generally in accord \nwith the standards accepted at the time of publication. However, in view of the \npossibility of human error or changes in medical sciences, neither the authors \nnor the publisher nor any other party who has been involved in the preparation \nor publication of this work warrants that the information contained herein is in \nevery respect accurate or complete, and they disclaim all responsibility for any \nerrors or omissions or the results obtained from use of the information contained \nin this work. Readers are encouraged to confirm the information contained \nherein with other sources. For example and in particular, readers are advised to \ncheck the product information sheet included in the package of each drug they \nplan to administer to be certain that the information contained in this work is \naccurate and that changes have not been made in the recommended dose or in \nthe contraindications for administration. This recommendation is of particular \nimportance in connection with new or infrequently used drugs.\n\nNew Y ork  Chicago  San Francisco  Athens  Lisbon  London  Madrid \nMexico City  Milan  New Delhi  Singapore  Sydney  Toronto\nPharmacotherapy \nHandbook\nNinth Edition\nBarbara G. Wells, PharmD, FASHP , FCCP\nDean Emeritus and Professor Emeritus \nExecutive Director Emeritus, Research Institute of Pharmaceutical Sciences \nSchool of Pharmacy, The University of Mississippi \nOxford, Mississippi\nJoseph T. DiPiro, PharmD, FCCP\nProfessor and Dean \nArchie O. McCalley Chair \nSchool of Pharmacy \nVirginia Commonwealth University \nRichmond, Virginia\nTerry L. Schwinghammer, PharmD, FCCP , FASHP , FAPhA, BCPS\nProfessor and Chair, Department of Clinical Pharmacy \nSchool of Pharmacy, West Virginia University \nMorgantown, West Virginia\nCecily V. DiPiro, PharmD\nConsultant Pharmacist \nRichmond, Virginia",
    "word_count": 319,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0001",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 1,
    "text": "Copyright © 2015 by McGraw-Hill Education. All rights reserved. Except as permitted \nunder the United States Copyright Act of 1976, no part of this publication may be re-\nproduced or distributed in any form or by any means, or stored in a database or retrieval \nsystem, without the prior written permission of the publisher.\nISBN: 978-0-07-182129-2\nMHID: 0-07-182129-5\nThe material in this eBook also appears in the print version of this title: ISBN: 978-0-07-182128-5,\nMHID: 0-07-182128-7.\neBook conversion by codeMantra\nVersion 1.0\nAll trademarks are trademarks of their respective owners. Rather than put a  \ntrademark symbol after every occurrence of a trademarked name, we use names in an \neditorial fashion only, and to the benefit of the trademark owner, with no intention of  \ninfringement of the trademark. Where such designations appear in this book, they have \nbeen printed with initial caps.\nMcGraw-Hill Education eBooks are available at special quantity discounts to use as \npremiums and sales promotions or for use in corporate training programs. To contact a \nrepresentative, please visit the Contact Us page at www.mhprofessional.com.\nPrevious edition copyright © 2012, 2006, 2003, 2000, by The McGraw-Hill  \nCompanies, Inc.; copyright © 1998 by Appleton & Lange.\nTERMS OF USE\nThis is a copyrighted work and McGraw-Hill Education and its licensors reserve \nall rights in and to the work. Use of this work is subject to these terms. Except as  \npermitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the \nwork, you may not decompile, disassemble, reverse engineer, reproduce, modify, create  \nderivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense \nthe work or any part of it without McGraw-Hill Education’s prior consent. You may use the \nwork for your own noncommercial and personal use; any other use of the work is strictly  \nprohibited. Your right to use the work may be terminated if you fail to comply with \nthese terms.\nTHE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND \nITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE  \nACCURACY , ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE \nOBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION \nTHAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR  \nOTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY , EXPRESS \nOR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRAN-\nTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.",
    "word_count": 392,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0002",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 2,
    "text": "Your right to use the work may be terminated if you fail to comply with \nthese terms.\nTHE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND \nITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE  \nACCURACY , ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE \nOBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION \nTHAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR  \nOTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY , EXPRESS \nOR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRAN-\nTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.  \nMcGraw-Hill Education and its licensors do not warrant or guarantee that the  \nfunctions contained in the work will meet your requirements or that its operation will be  \nuninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be \nliable to you or anyone else for any inaccuracy, error or omission, regardless of cause, \nin the work or for any damages resulting therefrom. McGraw-Hill Education has no \nresponsibility for the content of any information accessed through the work. Under \nno circumstances shall McGraw-Hill Education and/or its licensors be liable for any \nindirect, incidental, special, punitive, consequential or similar damages that result from \nthe use of or inability to use the work, even if any of them has been advised of the  \npossibility of such damages. This limitation of liability shall apply to any claim or cause \nwhatsoever whether such claim or cause arises in contract, tort or otherwise.",
    "word_count": 238,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0003",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 3,
    "text": "v\nFM_H1Contents\nPreface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix\nAcknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x\nSECTION 1: BONE AND JOINT DISORDERS\nEdited by Terry L. Schwinghammer\n1. Gout and Hyperuricemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1\n2. Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9\n3. Osteoporosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16\n4. Rheumatoid Arthritis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26\nSECTION  2: CARDIOvASCul AR DISORDERS\nEdited by Terry L. Schwinghammer\n 5. Acute Coronary Syndromes . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0004",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 4,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . .37\n 6. Arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .48\n 7. Cardiac Arrest  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .59\n 8.  Dyslipidemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .65\n 9.  Heart Failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75\n10. Hypertension  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .87\n11. Ischemic Heart Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .102\n12. Shock . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0005",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 5,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .111\n13. Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .120\n14. Venous Thromboembolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .125\nSECTION 3: DERMATO l OGIC DISORDERS\nEdited by Terry L. Schwinghammer\n15. Acne Vulgaris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .135\n16. Dermatologic Drug Reactions and Common Skin Conditions  . . . . . . . . . . . . . .141\n17. Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .147\nSECTION 4: E NDOCRINO l OGIC DISORDERS\nEdited by Terry L. Schwinghammer\n18. Adrenal Gland Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .155\n19.  Diabetes Mellitus . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0006",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 6,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .161\n20. Thyroid Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .176\nSECTION  5: GASTROINTESTINA l  DISORDERS\nEdited by Joseph T. DiPiro and Terry L. Schwinghammer\n21. Cirrhosis and Portal Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .185\n22. Constipation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .194\n23. Diarrhea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .200\n24. Gastroesophageal Reflux Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .206\n25. Hepatitis, Viral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213",
    "word_count": 367,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0007",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 7,
    "text": "vi\nContents\n26. Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .221\n27. Nausea and Vomiting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .231\n28. Pancreatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .244\n29. Peptic Ulcer Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .251\nSECTION 6: GYNECO l OGIC AND OBSTETRIC DISORDERS  \nEdited by Barbara G. Wells\n30. Contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257\n31. Menopausal, Perimenopausal, and Postmenopausal Hormone Therapy . . . . . . .276\n32. Pregnancy and Lactation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .291\nSECTION 7: HEMATO l OGIC DISORDERS\nEdited by Cecily V . DiPiro\n33. Anemias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0008",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 8,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . .301\n34. Sickle Cell Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .308\nSECTION 8: INFECTIO u S DISEASES\nEdited by Joseph T. DiPiro\n35. Antimicrobial Regimen Selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .313\n36. Central Nervous System Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .323\n37. Endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .333\n38. Fungal Infections, Invasive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .347\n39. Gastrointestinal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .361\n40. Human Immunodeficiency Virus Infection  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .368\n41. Influenza . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0009",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 9,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .387\n42. Intraabdominal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .394\n43. Respiratory Tract Infections, Lower . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .405\n44. Respiratory Tract Infections, Upper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .418\n45.  Sepsis and Septic Shock  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .427\n46. Sexually Transmitted Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .433\n47. Skin and Soft-Tissue Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .448\n48.  Surgical Prophylaxis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .466\n49. Tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0010",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 10,
    "text": ". . . . . . . . . . . . . . . . . . . . . . .476\n50. Urinary Tract Infections  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .490\n51. Vaccines, Toxoids, and Other Immunobiologics. . . . . . . . . . . . . . . . . . . . . . . . . . .500\nSECTION 9: N Eu ROl OGIC DISORDERS\nEdited by Barbara G. Wells\n52. Alzheimer’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .511\n53. Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .518\n54. Headache: Migraine and Tension-Type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .543\n55. Pain Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .557\n56. Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .578\n57. Status Epilepticus . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0011",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 11,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .587",
    "word_count": 39,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0012",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 12,
    "text": "vii\nContents\nSECTION 10: N u TRITION S u PPORT\nEdited by Cecily V . DiPiro\n58. Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .599\n59. Nutrition Evaluation and Support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .605\nSECTION 11: ONCO l OGIC DISORDERS\nEdited by Cecily V . DiPiro\n60. Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .619\n61. Colorectal Cancer  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .631\n62. Lung Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .642\n63. Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .647\n64. Prostate Cancer  . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0013",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 13,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . .654\nSECTION 12: OPHTHA l MIC DISORDERS\nEdited by Cecily V . DiPiro\n65. Glaucoma  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .665\nSECTION 13: PSYCHIATRIC DISORDERS\nEdited by Barbara G. Wells\n66. Anxiety Disorders  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .673\n67. Bipolar Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .694\n68. Major Depressive Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .712\n69. Schizophrenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .731\n70. Sleep-Wake Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .747\n71. Substance-Related Disorders . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0014",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 14,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . .755\nSECTION 14: RENA l  DISORDERS  \nEdited by Cecily V . DiPiro \n72. Acid–Base Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .771\n73. Acute Kidney Injury  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .779\n74. Chronic Kidney Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .787\n75. Electrolyte Homeostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .798\nSECTION 15: RESPIRATORY DISORDERS  \nEdited by Terry L. Schwinghammer \n76. Allergic Rhinitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .813\n77. Asthma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .821\n78. Chronic Obstructive Pulmonary Disease . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0015",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 15,
    "text": ". . . . . . . . . . . . . . .835\nSECTION 16: u ROl OGIC DISORDERS  \nEdited by Cecily V . DiPiro \n79. Benign Prostatic Hyperplasia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .845\n80. Erectile Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .850\n81. Urinary Incontinence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .865",
    "word_count": 179,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0016",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 16,
    "text": "viii\nAPPENDICES\nEdited by Barbara G. Wells\nAppendix 1. Allergic and Pseudoallergic Drug Reactions  . . . . . . . . . . . . . . . . . . . . . .873\nAppendix 2. Geriatrics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .877\nAppendix 3. Drug-Induced Hematologic Disorders  . . . . . . . . . . . . . . . . . . . . . . . . . .882\nAppendix 4. Drug-Induced Liver Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .887\nAppendix 5. Drug-Induced Pulmonary Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .889\nAppendix 6. Drug-Induced Kidney Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .898\nIndex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .903\nContents",
    "word_count": 303,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0017",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 17,
    "text": "ix\nFM_H1Preface\nThe pocket companion to Pharmacotherapy: A Pathophysiologic Approach, 9th edition, \nis designed to provide practitioners and students with critical information that can be \neasily used to guide drug therapy decision making in the clinical setting. To ensure \nbrevity and portability, the bulleted format provides the user with essential textual \ninformation, key tables and figures, and treatment algorithms. In order to reduce the \nnumber of pages and thus allow it to fit more easily in a pocket, the publisher under -\ntook a slight redesign to save space, and the authors made every effort to write as clearly \nand succinctly as possible.\nCorresponding to the major sections in the main text, disorders are alphabetized \nwithin the following sections: Bone and Joint Disorders, Cardiovascular Disorders, \nDermatologic Disorders, Endocrinologic Disorders, Gastrointestinal Disorders, \nGynecologic and Obstetric Disorders, Hematologic Disorders, Infectious Diseases, \nNeurologic Disorders, Nutritional Disorders, Oncologic Disorders, Ophthalmic \nDisorders, Psychiatric Disorders, Renal Disorders, Respiratory Disorders, and Urologic \nDisorders. Drug-induced conditions associated with allergic and pseudoallergic reac-\ntions, hematologic disorders, liver diseases, pulmonary disorders, and kidney disease \nappear in five tabular appendices. Information on the management of pharmacothera-\npy in the elderly is also included as an appendix.\nEach chapter is organized in a consistent format:\n•\tDisease state definition \n•\tPathophysiology\n•\tClinical presentation\n•\tDiagnosis\n•\tTreatment\n•\tEvaluation of therapeutic outcomes\nThe treatment section may include goals of treatment, general approach to treat-\nment, nonpharmacologic therapy, drug selection guidelines, dosing recommendations, \nadverse effects, pharmacokinetic considerations, and important drug-drug interac-\ntions. When more in-depth information is required, the reader is encouraged to refer to \nthe primary text, Pharmacotherapy: A Pathophysiologic Approach, 9th edition.\nIt is our sincere hope that students and practitioners find this book helpful as they \ncontinuously strive to deliver highest-quality patient-centered care. We invite your \ncomments on how we may improve subsequent editions of this work.\nBarbara G. Wells\nJoseph T. DiPiro\nTerry L. Schwinghammer\nCecily V . DiPiro\nPlease provide your comments about this book—Wells et al, Pharmacotherapy \nHandbook, 9th edition—to its authors and publisher by writing to pharmacotherapy@\nmcgraw-hill.com. Please indicate the author and title of this handbook in the subject \nline of your e-mail.",
    "word_count": 359,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0018",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 18,
    "text": "x\nFM_H1Acknowledgments\nThe editors wish to express their sincere appreciation to the authors whose chapters in \nthe 9th edition of Pharmacotherapy: A Pathophysiologic Approach served as the basis \nfor this book. The dedication and professionalism of these outstanding practitioners, \nteachers, and clinical scientists are evident on every page of this work. The authors \nof the chapters from the 9th edition are acknowledged at the end of each respective \nhandbook chapter.",
    "word_count": 70,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0019",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 19,
    "text": "1\nSECTION 1\nBONE AND JOINT DISORDERS\nEdited by Terry L.",
    "word_count": 11,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0020",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 20,
    "text": "1\nSECTION 1\nBONE AND JOINT DISORDERS\nEdited by Terry L. Schwinghammer\n•\tGout\t involves\t hyperuricemia, \t recurrent\t attacks\t of\t acute\t arthritis\t with\t mono­\nsodium\turate\t(MSU)\tcrystals \tin\tsynovial\tfluid\tleukocytes, \tdeposits\tof\tMSU\tcrystals \t\nin\t tissues\t in\t and\t around\t joints\t (tophi),\t interstitial\t renal\t disease,\t and\t uric\t acid\t\nnephrolithiasis.\nPATHOPHYSIOLOGY\n•\tUric\tacid\tis\tthe\tend\tproduct\tof\tpurine\tdegradation.\tAn\tincreased\turate\tpool\tin\tindi­\nviduals\twith\tgout\tmay\tresult\tfrom\toverproduction\tor\tunderexcretion.\n•\tPurines\t originate\t from\t dietary\t purine,\t conversion\t of\t tissue\t nucleic\t acid\t to\t purine\t\nnucleotides,\tand\tde\tnovo\tsynthesis\tof\tpurine\tbases.\n•\tOverproduction\tof\turic\tacid\tmay\tresult\tfrom\tabnormalities\tin\tenzyme\tsystems\tthat\t\nregulate\tpurine\tmetabolism\t(eg,\tincreased\tactivity\tof\tphosphoribosyl\tpyrophosphate\t\n[PRPP]\tsynthetase\tor\tdeficiency\tof\thypoxanthine­guanine\tphosphoribosyl\ttransferase\t\t\n[HGPRT]).\n•\tUric\tacid\tmay\tbe\toverproduced\tbecause\tof\tincreased\tbreakdown\tof\ttissue\tnucleic\tacids,\t\nas\t with\t myeloproliferative\t and\t lymphoproliferative\t disorders.\t Cytotoxic\t drugs\t can\t\nresult\tin\toverproduction\tof\turic\tacid\tdue\tto\tlysis\tand\tthe\tbreakdown\tof\tcellular\tmatter.\n•\tDietary\t purines\t are\t insignificant\t in\t generation\t of\t hyperuricemia\t without\t some\t\nderangement\tin\tpurine\tmetabolism\tor\telimination.\n•\tTwo\t thirds\t of\t uric\t acid\t produced\t daily\t is\t excreted\t in\t urine.\t The\t remainder\t is\t\neliminated\tthrough\tgastrointestinal\t(GI)\ttract\tafter\tdegradation\tby\tcolonic\tbacteria.\t\nDecline\tin\turinary\texcretion\tto\ta\tlevel\tbelow\trate\tof\tproduction\tleads\tto\thyperurice­\nmia\tand\tincreased\tpool\tof\tsodium\turate.\n•\tDrugs\tthat\tdecrease\trenal\turic\tacid\tclearance\tinclude\tdiuretics,\tnicotinic\tacid,\tsalicy­\nlates\t (<2\t g/day),\t ethanol,\t pyrazinamide,\t levodopa,\t ethambutol,\t cyclosporine,\t and\t\ncytotoxic\tdrugs.\n•\tDeposition\tof\turate\tcrystals\tin\tsynovial\tfluid\tresults\tin\tinflammation,\tvasodilation,\t\nincreased\t vascular\t permeability,\t complement\t activation,\t and\t chemotactic\t activity\t\nfor\t polymorphonuclear\t leukocytes.\t Phagocytosis\t of\t urate\t crystals\t by\t leukocytes\t\nresults\tin\trapid\tlysis\tof\tcells\tand\tdischarge\tof\tproteolytic\tenzymes\tinto\tcytoplasm.\t\nThe\t ensuing\t inflammatory\t reaction\t causes\t intense\t joint\t pain,\t erythema,\t warmth,\t\nand\tswelling.\n•\tUric\tacid\tnephrolithiasis\toccurs\tin\t10%\tto\t25%\tof\tpatients\twith\tgout.\tPredisposing\t\nfactors\t include\t excessive\t urinary\t excretion\t of\t uric\t acid,\t acidic\t urine,\t and\t highly\t\nconcentrated\turine.\n•\tIn\tacute\turic\tacid\tnephropathy,\tacute\trenal\tfailure\toccurs\tbecause\tof\tblockage\tof\turine\t\nflow\tfrom\tmassive\tprecipitation\tof\turic\tacid\tcrystals\tin\tcollecting\tducts\tand\tureters.\t\nChronic\turate\tnephropathy\tis\tcaused\tby\tlong­term\tdeposition\tof\turate\tcrystals\tin\tthe\t\nrenal\tparenchyma.\n•\tT ophi\t(urate\tdeposits)\tare\tuncommon\tand\tare\ta\tlate\tcomplication\tof\thyperuricemia.\t\nMost\t common\t sites\t are\t the\t base\t of\t the\t fingers,\t olecranon\t bursae,\t ulnar\t aspect\t of\t\nforearm,\tAchilles\ttendon,\tknees,\twrists,\tand\thands.\nGout and Hyperuricemia\n1\nC H A P T E R",
    "word_count": 423,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0021",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 21,
    "text": "2\nSECTION 1     Bone and Joint Disorders\nCLINICAL PRESENTATION\n•\tAcute\t gout\t attacks\t are\t characterized\t by\t rapid\t onset\t of\t excruciating\t pain,\t swelling,\t\nand\tinflammation.\tThe\tattack\tis\ttypically\tmonoarticular,\tmost\toften\taffecting\tthe\tfirst\t\nmetatarsophalangeal\t joint\t (podagra),\t and\t then,\t in\t order\t of\t frequency,\t the\t insteps,\t\nankles,\t heels,\t knees,\twrists,\t fingers,\t and\t elbows.\t Attacks\tcommonly\t begin\t at\t night,\t\nwith\tthe\tpatient\tawakening\twith\texcruciating\tpain.\tAffected\tjoints\tare\terythematous,\t\nwarm,\tand\tswollen.\tFever\tand\tleukocytosis\tare\tcommon.\tUntreated\tattacks\tlast\tfrom\t\n3\tto\t14\tdays\tbefore\tspontaneous\trecovery.\n•\tAcute\t attacks\t may\t occur\t without\t provocation\t or\t be\t precipitated\t by\t stress,\t trauma,\t\nalcohol\t ingestion,\t infection,\t surgery,\t rapid\t lowering\t of\t serum\t uric\t acid\t by\t uric\t\nacid–lowering\t agents,\t and\t ingestion\t of\t drugs\t known\t to\t elevate\t serum\t uric\t acid\t\nconcentrations.\nDIAGNOSIS\n•\tDefinitive\t diagnosis\t requires\t aspiration\t of\t synovial\t fluid\t from\t the\t affected\t joint\t\nand\t identification\t of\t intracellular\t crystals\t of\t MSU\t monohydrate\t in\t synovial\t fluid\t\nleukocytes.\n•\tWhen\tjoint\taspiration\tis\tnot\tfeasible,\ta\tpresumptive\tdiagnosis\tis\tbased\ton\tpresence\tof\t\ncharacteristic\tsigns\tand\tsymptoms,\tas\twell\tas\tthe\tresponse\tto\ttreatment.\nTREATMENT\n•\tGoals\tof\tTreatment:\tT erminate\tthe\tacute\tattack,\tprevent\trecurrent\tattacks,\tand\tpre­\nvent\tcomplications\tassociated\twith\tchronic\tdeposition\tof\turate\tcrystals\tin\ttissues.\nACUTE GOUTY ARTHRITIS (F IG.",
    "word_count": 207,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0022",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 22,
    "text": "  Bone and Joint Disorders\nCLINICAL PRESENTATION\n•\tAcute\t gout\t attacks\t are\t characterized\t by\t rapid\t onset\t of\t excruciating\t pain,\t swelling,\t\nand\tinflammation.\tThe\tattack\tis\ttypically\tmonoarticular,\tmost\toften\taffecting\tthe\tfirst\t\nmetatarsophalangeal\t joint\t (podagra),\t and\t then,\t in\t order\t of\t frequency,\t the\t insteps,\t\nankles,\t heels,\t knees,\twrists,\t fingers,\t and\t elbows.\t Attacks\tcommonly\t begin\t at\t night,\t\nwith\tthe\tpatient\tawakening\twith\texcruciating\tpain.\tAffected\tjoints\tare\terythematous,\t\nwarm,\tand\tswollen.\tFever\tand\tleukocytosis\tare\tcommon.\tUntreated\tattacks\tlast\tfrom\t\n3\tto\t14\tdays\tbefore\tspontaneous\trecovery.\n•\tAcute\t attacks\t may\t occur\t without\t provocation\t or\t be\t precipitated\t by\t stress,\t trauma,\t\nalcohol\t ingestion,\t infection,\t surgery,\t rapid\t lowering\t of\t serum\t uric\t acid\t by\t uric\t\nacid–lowering\t agents,\t and\t ingestion\t of\t drugs\t known\t to\t elevate\t serum\t uric\t acid\t\nconcentrations.\nDIAGNOSIS\n•\tDefinitive\t diagnosis\t requires\t aspiration\t of\t synovial\t fluid\t from\t the\t affected\t joint\t\nand\t identification\t of\t intracellular\t crystals\t of\t MSU\t monohydrate\t in\t synovial\t fluid\t\nleukocytes.\n•\tWhen\tjoint\taspiration\tis\tnot\tfeasible,\ta\tpresumptive\tdiagnosis\tis\tbased\ton\tpresence\tof\t\ncharacteristic\tsigns\tand\tsymptoms,\tas\twell\tas\tthe\tresponse\tto\ttreatment.\nTREATMENT\n•\tGoals\tof\tTreatment:\tT erminate\tthe\tacute\tattack,\tprevent\trecurrent\tattacks,\tand\tpre­\nvent\tcomplications\tassociated\twith\tchronic\tdeposition\tof\turate\tcrystals\tin\ttissues.\nACUTE GOUTY ARTHRITIS (F IG. 1–1)\nNonpharmacologic Therapy\n•\tLocal\tice\tapplication\tis\tthe\tmost\teffective\tadjunctive\ttreatment.\tDietary\tsupplements\t\n(eg,\tflaxseed,\tcelery\troot)\tare\tnot\trecommended.\nPharmacologic Therapy\n•\tMost\tpatients\tmay\tbe\ttreated\tsuccessfully\twith\tnonsteroidal\tanti­inflammatory\tdrugs\t\n(NSAIDs),\tcorticosteroids,\tor\tcolchicine.\nNSAIDS\n•\tNSAIDs\t have\t excellent\t efficacy \t and\t minimal\t toxicity\t with\t short­term\t use.\t\nIndomethacin,\tnaproxen,\tand\tsulindac\thave\tFood\tand\tDrug\tAdministration\t(FDA)\t\napproval\tfor\tgout,\tbut\tothers\tare\tlikely\tto\tbe\teffective\t(Table 1–1).\n•\tStart\ttherapy\twithin\t24\thours\tof\tattack\tonset\tand\tcontinue\tuntil\tcomplete\tresolution\t\n(usually\t5–8\tdays).\tTapering\tmay\tbe\tconsidered\tafter\tresolution,\tespecially\tif\tcomor­\nbidities\tsuch\tas\thepatic\tor\trenal\tinsufficiency\tmake\tprolonged\ttherapy\tundesirable.\n•\tThe\tmost\tcommon\tadverse\teffects\tinvolve\tthe\tGI\ttract\t(gastritis,\tbleeding,\tperforation),\t\nkidneys\t(renal\tpapillary\tnecrosis,\treduced\tcreatinine\tclearance\t[CLcr]),\tcardiovascular\t\nsystem\t (increased\t blood\t pressure,\t sodium\t and\t fluid\t retention),\t and\t central\t nervous\t\nsystem\t(CNS)\t(impaired\tcognitive\tfunction,\theadache,\tdizziness).\n•\tSelective\tcyclooxygenase­2\t(COX­2)\tinhibitors\t(eg,\tcelecoxib)\tmay\tbe\tan\toption\tfor\t\npatients\t unable\t to\t take\t nonselective\t NSAIDs,\t but\t the\t risk­to­benefit\t ratio\t in\t acute\t\ngout\tis\tunclear,\tand\tcardiovascular\trisk\tmust\tbe\tconsidered.\nCORTICOSTEROIDS\n•\tCorticosteroid\t efficacy\t is\t equivalent\t to\t NSAIDs;\t they\t can\t be\t used\t systemically\t\nor\t by\t intra­articular\t (IA)\t injection.\t Systemic\t therapy\t is\t necessary\t if\t an\t attack\t is\t\npolyarticular.",
    "word_count": 414,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0023",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 23,
    "text": "3\nGout and Hyperuricemia  |  CHAPTER 1\nPain intensity\nTreatment outcome Treatment Outcome\nInadequate\nresponsed\nSuccessful\naEvidence Grade Level A: Supported by multiple randomized clinical trials or meta-analysesbEvidence Grade Level B: Derived from a single randomized trial, or nonrandomized studiescEvidence Grade Level C: Consensus opinion of experts, case studies, or standard-of-cared‘Inadequate Response’ is defined as <20% improvement in pain score within 24 hours or <50% at ≥ 24 hourseColchicine is recommended only if started within 36 hours of symptom onset\nSwitch to Alternative Monotherapyc\nOff-Label Therapies in Development\n• Interleukin-1 Inhibitor Therapy\nMild/Moderate\nInitiate Monotherapy:a\n• NSAIDa \n• Colchicinea,e\n• Systemic corticosteroida\n Inadequate responseSuccessful d\nPrevent Recurrent Attacks\n• Recommend dietary modifications to\nprevent hyperuricemiab\n• Educate patient about the role of uric \nacid excess in gout attacksb\n• Develop plan for patient to promptly self-\ntreat any future attacksb\n• Initiate urate-lowering therapy if indicated\n(see textbook Fig. 74-6 for further detail on\nurate-lowering therapy)\nc\nSevere\nInitiate Combination Therapy:c\n• Colchicine + NSAID\n• Colchicine + Oral corticosteroid\n• NSAID + Intra-articular corticosteroid\n• Colchicine + Intra-articular corticosteroid\n• Oral corticosteroid + Intra-articular corticosteroid\nFIGURE 1–1.  Algorithm for management of an acute gout attack.",
    "word_count": 196,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0024",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 24,
    "text": "4\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0025",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 25,
    "text": "4\nSECTION 1     Bone and Joint Disorders\n•\tPrednisone\tor\tprednisolone\toral\tdosing\tstrategies:\t(1)\t0.5\tmg/kg\tdaily\tfor\t5\tto\t10\t\ndays\tfollowed\tby\tabrupt\tdiscontinuation;\tor\t(2)\t0.5\tmg/kg\tdaily\tfor\t2\tto\t5\tdays\tfol­\nlowed\tby\ttapering\tfor\t7\tto\t10\tdays.\tTapering\tis\toften\tused\tto\treduce\tthe\thypothetical\t\nrisk\tof\ta\trebound\tattack\tupon\tsteroid\twithdrawal.\n•\tMethylprednisolone dose pack\tis\ta\t6­day\tregimen\tstarting\twith\t24\tmg\ton\tday\t1\tand\t\ndecreasing\tby\t4\tmg\teach\tday.\n•\tTriamcinolone acetonide\t 20–40\t mg\t given\t by\t IA\t injection\t may\t be\t used\t if\t gout\t is\t\nlimited\t to\t one\t or\t two\t joints.\t IA\t corticosteroids\t should\t generally\t be\t used\t with\t oral\t\nNSAID,\tcolchicine,\tor\tcorticosteroid\ttherapy.\n•\tMethylprednisolone\t (a\t long­acting\t corticosteroid)\t given\t by\t a\t single\t intramuscu­\nlar\t (IM)\t injection\t followed\t by\t oral\t corticosteroid\t therapy\t is\t another\t reasonable\t\napproach.\t Alternatively,\t IM\t corticosteroid\t monotherapy\t may\t be\t considered\t in\t\npatients\twith\tmultiple\taffected\tjoints\twho\tcannot\ttake\toral\ttherapy.\t\n•\tShort­term\tcorticosteroid\tuse\tis\tgenerally\twell\ttolerated.\tUse\twith\tcaution\tin\tpatients\t\nwith\tdiabetes,\tGI\tproblems,\tbleeding\tdisorders,\tcardiovascular\tdisease,\tand\tpsychi­\natric\tdisorders.\tAvoid\tlong­term\tuse\tbecause\tof\trisk\tfor\tosteoporosis,\thypothalamic–\npituitary–adrenal\taxis\tsuppression,\tcataracts,\tand\tmuscle\tdeconditioning.\n•\tAdrenocorticotropic hormone (ACTH) \t gel\t 40\t to\t 80\t USP\t units\t may\t be\t given\t IM\t\nevery\t6\tto\t8\thours\tfor\t2\tor\t3\tdays\tand\tthen\tdiscontinued.\tLimit\tuse\tfor\tpatients\twith\t\ncontraindications\tto\tfirst­line\ttherapies\t(eg,\theart\tfailure,\tchronic\trenal\tfailure,\this­\ntory\tof\tGI\tbleeding)\tor\tpatients\tunable\tto\ttake\toral\tmedications.\nCOLCHICINE\n•\tColchicine\tis\thighly\teffective\tin\trelieving\tacute\tgout\tattacks;\twhen\tit\tis\tstarted\twithin\t\nthe\tfirst\t24\thours\tof\tonset,\tabout\ttwo\tthirds\tof\tpatients\trespond\twithin\thours.\tUse\t\nonly\twithin\t36\thours\tof\tattack\tonset\tbecause\tthe\tlikelihood\tof\tsuccess\tdecreases\tsub­\nstantially\tif\ttreatment\tis\tdelayed.\n TABLE 1–1   Dosage Regimens of Oral Nonsteroidal Anti-inflammatory Drugs for \nTreatment of Acute Gout\nGeneric Name Initial Dose Usual Range\nEtodolac 300 mg twice daily 300–500 mg twice daily\nFenoprofen 400 mg three times daily 400–600 mg three to four times \ndaily\nIbuprofen 400 mg three times daily 400–800 mg three to four times \ndaily\nIndomethacin 50 mg three times daily 50 mg three times daily initially \nuntil pain is tolerable then rapidly \nreduce to complete cessation\nKetoprofen 75 mg three times daily or 50 mg \nfour times daily\n50–75 mg three to four times daily\nNaproxen 750 mg followed by 250 mg every \n8 h until the attack has subsided\n—\nPiroxicam 20 mg once daily or 10 mg twice \ndaily\n—\nSulindac 150 mg twice daily 150–200 mg twice daily for 7–10 \ndays\nCelecoxib 800 mg followed by 400 mg on \nday 1, then 400 mg twice daily \nfor 1 week\n—",
    "word_count": 457,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0026",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 26,
    "text": "5\nGout and Hyperuricemia     CHAPTER 1\n•\tColchicine\tcauses\tdose­dependent\tGI\tadverse\teffects\t(nausea,\tvomiting,\tand\tdiarrhea).\t\t\nNon­GI\teffects\tinclude\tneutropenia\tand\taxonal\tneuromyopathy,\twhich\tmay\tbe\twors­\nened\t in\tpatients\t taking\t other\t myopathic\t drugs\t (eg,\t statins)\t or\t in\trenal\t insufficiency.\t\t\nDo\t not\t use\t concurrently\t with\t P­glycoprotein\t or\t strong\t CYP450\t 3A4\t inhibitors\t\t\n(eg,\t clarithromycin)\tbecause\t reduced\tbiliary\t excretion\tmay\tlead\t to\tincreased\tplasma\t\ncolchicine\tlevels\tand\ttoxicity.\tUse\twith\tcaution\tin\trenal\tor\thepatic\tinsufficiency.\n•\tColcrys\tis\tan\tFDA­approved\tcolchicine\tproduct\tavailable\tin\t0.6\tmg\toral\ttablets.\tThe\t\nrecommended\tdose\tis\t1.2\tmg\t(two\ttablets)\tinitially,\tfollowed\tby\t0.6\tmg\t(one\ttablet)\t\n1\t hour\t later.\t Although\t not\t an\t FDA­approved\t regimen,\t the\t American\t College\t of\t\nRheumatology\t(ACR)\tgout\ttreatment\tguidelines\tsuggest\tthat\tcolchicine\t0.6\tmg\tonce\t\nor\ttwice\tdaily\tcan\tbe\tstarted\t12\thours\tafter\tthe\tinitial\t1.2\tmg\tdose\tand\tcontinued\tuntil\t\nthe\tattack\tresolves.\nHYPERURICEMIA IN GOUT \n•\tRecurrent\t gout\t attacks\t can\t be\t prevented\t by\t maintaining\t low\t uric\t acid\t levels,\t but\t\nadherence\twith\tnonpharmacologic\tand\tpharmacologic\ttherapies\tis\tpoor.\nNonpharmacologic Therapy\n•\tPatient\teducation\t should\t address\tthe\trecurrent\tnature\t of\t gout\t and\t the\t objective\tof\t\neach\tlifestyle/dietary\tmodification\tand\tmedication.\n•\tPromote\tweight\tloss\tthrough\tcaloric\trestriction\tand\texercise\tin\tall\tpatients\tto\tenhance\t\nrenal\turate\texcretion.\n•\tAlcohol\trestriction\tis\timportant\tbecause\t consumption\tcorrelates\twith\tgout\tattacks.\t\nACR\tguidelines\trecommend\tlimiting\talcohol\tuse\tin\tall\tgout\tpatients\tand\tavoidance\t\nof\tany\talcohol\tduring\tperiods\tof\tfrequent\tgout\tattacks\tand\tin\tpatients\twith\tadvanced\t\ngout\tunder\tpoor\tcontrol.\n•\tDietary\trecommendations\tinclude\tlimiting\tconsumption\tof\thigh­fructose\tcorn\tsyrup\t\nand\tpurine­rich\tfoods\t(organ\tmeats\tand\tsome\tseafood)\tand\tencouraging\tconsump­\ntion\tof\tvegetables\tand\tlow­fat\tdairy\tproducts.\n•\tEvaluate\tthe\tmedication\tlist\tfor\tpotentially\tunnecessary\tdrugs\tthat\tmay\televate\turic\t\nacid\tlevels.\tGout\tis\tnot\tnecessarily\ta\tcontraindication\tto\tuse\tof\tthiazide\tdiuretics\tin\t\nhypertensive\t patients.\t Low­dose\t aspirin\t for\t cardiovascular\t prevention\t should\t be\t\ncontinued\tin\tpatients\twith\tgout\tbecause\taspirin\thas\ta\tnegligible\teffect\ton\televating\t\nserum\turic\tacid.\nPharmacologic Therapy (Fig.",
    "word_count": 333,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0027",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 27,
    "text": "  CHAPTER 1\n•\tColchicine\tcauses\tdose­dependent\tGI\tadverse\teffects\t(nausea,\tvomiting,\tand\tdiarrhea).\t\t\nNon­GI\teffects\tinclude\tneutropenia\tand\taxonal\tneuromyopathy,\twhich\tmay\tbe\twors­\nened\t in\tpatients\t taking\t other\t myopathic\t drugs\t (eg,\t statins)\t or\t in\trenal\t insufficiency.\t\t\nDo\t not\t use\t concurrently\t with\t P­glycoprotein\t or\t strong\t CYP450\t 3A4\t inhibitors\t\t\n(eg,\t clarithromycin)\tbecause\t reduced\tbiliary\t excretion\tmay\tlead\t to\tincreased\tplasma\t\ncolchicine\tlevels\tand\ttoxicity.\tUse\twith\tcaution\tin\trenal\tor\thepatic\tinsufficiency.\n•\tColcrys\tis\tan\tFDA­approved\tcolchicine\tproduct\tavailable\tin\t0.6\tmg\toral\ttablets.\tThe\t\nrecommended\tdose\tis\t1.2\tmg\t(two\ttablets)\tinitially,\tfollowed\tby\t0.6\tmg\t(one\ttablet)\t\n1\t hour\t later.\t Although\t not\t an\t FDA­approved\t regimen,\t the\t American\t College\t of\t\nRheumatology\t(ACR)\tgout\ttreatment\tguidelines\tsuggest\tthat\tcolchicine\t0.6\tmg\tonce\t\nor\ttwice\tdaily\tcan\tbe\tstarted\t12\thours\tafter\tthe\tinitial\t1.2\tmg\tdose\tand\tcontinued\tuntil\t\nthe\tattack\tresolves.\nHYPERURICEMIA IN GOUT \n•\tRecurrent\t gout\t attacks\t can\t be\t prevented\t by\t maintaining\t low\t uric\t acid\t levels,\t but\t\nadherence\twith\tnonpharmacologic\tand\tpharmacologic\ttherapies\tis\tpoor.\nNonpharmacologic Therapy\n•\tPatient\teducation\t should\t address\tthe\trecurrent\tnature\t of\t gout\t and\t the\t objective\tof\t\neach\tlifestyle/dietary\tmodification\tand\tmedication.\n•\tPromote\tweight\tloss\tthrough\tcaloric\trestriction\tand\texercise\tin\tall\tpatients\tto\tenhance\t\nrenal\turate\texcretion.\n•\tAlcohol\trestriction\tis\timportant\tbecause\t consumption\tcorrelates\twith\tgout\tattacks.\t\nACR\tguidelines\trecommend\tlimiting\talcohol\tuse\tin\tall\tgout\tpatients\tand\tavoidance\t\nof\tany\talcohol\tduring\tperiods\tof\tfrequent\tgout\tattacks\tand\tin\tpatients\twith\tadvanced\t\ngout\tunder\tpoor\tcontrol.\n•\tDietary\trecommendations\tinclude\tlimiting\tconsumption\tof\thigh­fructose\tcorn\tsyrup\t\nand\tpurine­rich\tfoods\t(organ\tmeats\tand\tsome\tseafood)\tand\tencouraging\tconsump­\ntion\tof\tvegetables\tand\tlow­fat\tdairy\tproducts.\n•\tEvaluate\tthe\tmedication\tlist\tfor\tpotentially\tunnecessary\tdrugs\tthat\tmay\televate\turic\t\nacid\tlevels.\tGout\tis\tnot\tnecessarily\ta\tcontraindication\tto\tuse\tof\tthiazide\tdiuretics\tin\t\nhypertensive\t patients.\t Low­dose\t aspirin\t for\t cardiovascular\t prevention\t should\t be\t\ncontinued\tin\tpatients\twith\tgout\tbecause\taspirin\thas\ta\tnegligible\teffect\ton\televating\t\nserum\turic\tacid.\nPharmacologic Therapy (Fig. 1–2)\n•\tAfter\tthe\tfirst\tattack\tof\tacute\tgout,\tprophylactic\tpharmacotherapy\tis\trecommended\t\nif\tpatients\thave\ttwo\tor\tmore\tattacks\tper\tyear,\teven\tif\tserum\turic\tacid\tis\tnormal\tor\t\nonly\tminimally\televated.\tOther\tindications\tinclude\tpresence\tof\ttophi,\tchronic\tkidney\t\ndisease,\tor\thistory\tof\turolithiasis.\n•\tUrate­lowering\t therapy\t can\t be\t started\t during\t an\t acute\t attack\t if\t anti­inflammatory\t\nprophylaxis\thas\tbeen\tinitiated.\n•\tThe\tgoal\tof\turate­lowering\ttherapy\tis\tto\tachieve\tand\tmaintain\tserum\turic\tacid\tless\t\nthan\t6\tmg/dL\t(357\tµmol/L),\tand\tpreferably\tless\tthan\t5\tmg/dL\t(297\tµmol/L)\tif\tsigns\t\nand\tsymptoms\tof\tgout\tpersist.\n•\tUrate\tlowering\tshould\tbe\tprescribed\tfor\tlong­term\tuse.\tSerum\turate\tcan\tbe\treduced\t\nby\t decreasing\t synthesis\t of\t uric\t acid\t (xanthine\t oxidase\t inhibitors)\t or\t by\t increasing\t\nrenal\texcretion\tof\turic\tacid\t(uricosurics).\t\n•\tApply\ta\tstep­wise\tapproach\tto\thyperuricemia\t(see\tFig.\t1–2).\tXanthine\toxidase\tinhibi­\ntors\tare\trecommended\tfirst­line\ttherapy;\tthe\turicosuric\tagent\tprobenecid\tis\trecom­\nmended\tas\talternative\ttherapy\tin\tpatients\twith\ta\tcontraindication\tor\tintolerance\tto\t\nxanthine\toxidase\tinhibitors.\tIn\trefractory\tcases,\tcombination\ttherapy\twith\ta\txanthine\t\noxidase\t inhibitor\t plus\t a\t drug\t with\t uricosuric\t properties\t (probenecid,\t losartan,\t or\t\nfenofibrate)\tis\tsuggested.\tPegloticase\tmay\tbe\tused\tin\tsevere\tcases\tin\twhich\tthe\tpatient\t\ncannot\ttolerate\tor\tis\tnot\tresponding\tto\tother\ttherapies.",
    "word_count": 539,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0028",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 28,
    "text": "6\nSECTION 1  |  Bone and Joint Disorders\nDoes patient have an indication for Urate-Lowering Therapy (ULT)?a\nAchieved\nurate target?\nContinue all measures needed to maintain serum\nurate <6 mg/dL indefinitelyd\naIndications for ULT include: (1) presence of tophus, (2) ≥2 gout attacks per year, (3) CKD stage 2 or worse, or (4) past urolithiasis\nbEvidence Grade Level A: Supported by multiple randomized clinical trials or meta-analyses\ncEvidence Grade Level B: Derived from a single randomized trial, or nonrandomized studies\ndEvidence Grade Level C: Consensus opinion of experts, case studies, or standard-of-care\nYes\nContinue prophylactic therapy\nTophus present?No Yes\nYes\nYes\nNo\nNo\nNonpharmacologic Urate-Lowering Strategiesd\nDietary Modifications\n• Reduce/avoid alcohol and organ meats\n• Increase vegetable and dairy consumption\nEliminate Urate-Elevating Medications if Unnecessary\n• Diuretics\n• Niacin\n• Calcineurin inhibitors \nDiscontinue prophylactic\ntherapy after the greater of:\n1)  6 monthsb\n             OR\n2)  3 months following\n     achievement of urate\n     targetc\nTitrate ULT to\nmaximum dose\nDiscontinue\nprophylactic\ntherapy after\n6 months\nfollowing\nachievement of\nurate targetd\nYes\nNo\nNo\nNo\nYes\nAntiinflammatory Gout Prophylaxis During ULT Initiation\nFirst-Line\n• Low-dose colchicineb\n• Low-dose NSAIDd\nSecond-Line\n• Low-dose prednisone or prednisoloned\nEvidence of gout activity\nwhile taking ULT?\nULT Initiation\nFirst-Line\n• Xanthine Oxidase Inhibitor (XOI)b\n• Allopurinol\n• Febuxostat\nAlternative\n• Probenecidc\nAchieved\nurate target?\nIf using XOI,\nadd uricosuric therapy\n• Probenecid\n• Fenofibrate\n• Losartan\nAchieved\nUrate Target?\nSwitch to\npegloticase\nFIGURE 1–2.  Algorithm for management of hyperuricemia in gout.",
    "word_count": 243,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0029",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 29,
    "text": "7\nGout and Hyperuricemia  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0030",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 30,
    "text": "7\nGout and Hyperuricemia     CHAPTER 1\nXANTHINE  OXIDASE INHIb ITORS\n•\tXanthine\t oxidase\t inhibitors\t reduce\t uric\t acid\tby\timpairing\t conversion\t of\t hypoxan­\nthine\tto\txanthine\tand\txanthine\tto\turic\tacid.\tBecause\tthey\tare\teffective\tin\tboth\tover­\nproducers\tand\tunderexcretors\tof\turic\tacid,\tthey\tare\tthe\tmost\twidely\tprescribed\tagents\t\nfor\tlong­term\tprevention\tof\trecurrent\tgout\tattacks.\n•\tAllopurinol\t lowers\t uric\t acid\t levels\t in\t a\t dose­dependent\t manner.\t ACR\t guidelines\t\nrecommend\ta\tstarting\tdose\tno\tgreater\tthan\t100\tmg\tdaily\tand\tthen\tgradually\ttitrating\t\nevery\t2\tto\t5\tweeks\tup\tto\ta\tmaximum\tdose\tof\t800\tmg/day\tuntil\tthe\tserum\turate\ttarget\t\nis\tachieved.\tPatients\twith\tchronic\tkidney\tdisease\t(stage\t4\tor\tworse)\tshould\tstart\tat\ta\t\ndose\tno\tgreater\tthan\t50\tmg\tper\tday.\tConservative\tdosing\tis\tintended\tto\tavoid\tallo­\npurinol\thypersensitivity\t syndrome\tand\tprevent\t acute\t gout\t attacks\tcommon\t during\t\ninitiation\tof\turate­lowering\ttherapy.\t\n•\tMild\t adverse\t effects\t of\t allopurinol\t include\t skin\t rash,\t leukopenia,\t GI\t problems,\t\nheadache,\t and\t urticaria.\t More\t severe\t adverse\t reactions\t include\t severe\t rash\t (toxic\t\nepidermal\tnecrolysis,\terythema\tmultiforme,\tor\texfoliative\tdermatitis)\tand\tallopurinol\t\nhypersensitivity\tsyndrome\tcharacterized\tby\tfever,\teosinophilia,\tdermatitis,\tvasculitis,\t\nand\t renal\t and\t hepatic\t dysfunction\t that\t occurs\t rarely\t but\t is\t associated\t with\t a\t 20%\t\nmortality\trate.\n•\tFebuxostat\t(Uloric)\talso\tlowers\tserum\turic\tacid\tin\ta\tdose­dependent\tmanner.\tThe\t\nrecommended\tstarting\tdose\tis\t40\tmg\tonce\tdaily.\tIncrease\tthe\tdose\tto\t80\tmg\tonce\tdaily\t\nfor\tpatients\twho\tdo\tnot\tachieve\ttarget\tserum\turic\tacid\tconcentrations\tafter\t2 weeks\tof\t\ntherapy.\tFebuxostat\tis\twell\ttolerated,\twith\tadverse\tevents\tof\tnausea,\tarthralgias,\tand\t\nminor\thepatic\ttransaminase\televations.\tFebuxostat\tdoes\tnot\trequire\tdose\tadjustment\t\nin\tmild\tto\tmoderate\thepatic\tor\trenal\tdysfunction.\tDue\tto\trapid\tmobilization\tof\turate\t\ndeposits\tduring\tinitiation,\tgive\tconcomitant\ttherapy\twith\tcolchicine\tor\tan\tNSAID\tfor\t\nat\tleast\tthe\tfirst\t8\tweeks\tof\ttherapy\tto\tprevent\tacute\tgout\tflares.\nURICOSURICS\n•\tProbenecid\t increases\t renal\t clearance\t of\t uric\t acid\t by\t inhibiting\t the\t postsecretory\t\nrenal\t proximal\t tubular\t reabsorption\t of\t uric\t acid.\t Patients\t with\t a\t history\t of\t uroli­\nthiasis\tshould\tnot\treceive\turicosurics.\tStart\ttherapy\twith\turicosurics\tat\ta\tlow\tdose\tto\t\navoid\tmarked\turicosuria\tand\tpossible\tstone\tformation.\tMaintaining\tadequate\turine\t\nflow\tand\talkalinization\tof\tthe\turine\tduring\tthe\tfirst\tseveral\tdays\tof\ttherapy\tmay\talso\t\ndecrease\tlikelihood\tof\turic\tacid\tstone\tformation.\n•\tInitial\tprobenecid\tdose\tis\t250\tmg\ttwice\tdaily\tfor\t1\tto\t2\tweeks,\tthen\t500\tmg\ttwice\tdaily\t\nfor\t2\tweeks.\tIncrease\tthe\tdaily\tdose\tthereafter\tby\t500­mg\tincrements\tevery\t1\tto\t2\tweeks\t\nuntil\tsatisfactory\tcontrol\tis\tachieved\tor\ta\tmaximum\tdose\tof\t2\tg/day\tis\treached.\n•\tMajor\t side\t effects\t of\t probenecid\t include\t GI\t irritation,\t rash\t and\t hypersensitivity,\t\nprecipitation\tof\tacute\tgouty\tarthritis,\tand\tstone\tformation.\tContraindications\tinclude\t\nimpaired\t renal\t function\t (CLcr\t <50\t mL/min\t or\t <0.84\t mL/s)\t and\t overproduction\t of\t\nuric\tacid.\nPEGLOTICASE\n•\tPegloticase\t (Krystexxa)\t is\t a\t pegylated\t recombinant\t uricase\t that\t reduces\t serum\t\nuric\tacid\tby\tconverting\turic\tacid\tto\tallantoin,\twhich\tis\twater\tsoluble.\tPegloticase\tis\t\nindicated\tfor\tantihyperuricemic\ttherapy\tin\tadults\trefractory\tto\tconventional\ttherapy.\t\n•\tThe\t dose\t is\t 8\t mg\t by\t IV\t infusion\t over\t at\t least\t 2\t hours\t every\t 2\t weeks.\t Because\t of\t\npotential\t infusion­related\t allergic\t reactions,\t patients\t must\t be\t pretreated\t with\t anti­\nhistamines\t and\t corticosteroids.\t Pegloticase\t is\t substantially\t more\t expensive\t than\t\nfirst­line\turate­lowering\ttherapies.\n•\tThe\tideal\tduration\tof\tpegloticase\ttherapy\tis\tunknown.\tDevelopment\tof\tpegloticase\t\nantibodies\tresulting\tin\tloss\tof\tefficacy\tmay\tlimit\tthe\tduration\tof\teffective\ttherapy.\t\n•\tBecause\tof\tits\tlimitations,\treserve\tpegloticase\tfor\tpatients\twith\trefractory\tgout\twho\t\nare\tunable\tto\ttake\tor\thave\tfailed\tall\tother\turate­lowering\ttherapies.",
    "word_count": 589,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0031",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 31,
    "text": "8\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0032",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 32,
    "text": "8\nSECTION 1     Bone and Joint Disorders\nANTIIFLAMMATORY PROPHYLAXIS DURING INITIATION  \nOF URATE-LOWERING THERAPY\n•\tInitiation\tof\turate­lowering\ttherapy\tcan\tprecipitate\tan\tacute\tgout\tattack\tdue\tto\tremod­\neling\t of\t urate\t crystal\t deposits\t in\t joints\t after\t rapid\t lowering\t of\t urate\t concentrations.\t\nProphylactic\tantiinflammatory\ttherapy\tshould\tbe\tused\tto\tprevent\tsuch\tgout\tattacks.\n•\tThe\tACR\tguidelines\trecommend\tlow­dose\toral\tcolchicine\t(0.6\tmg\ttwice\tdaily)\tand\t\nlow­dose\tNSAIDs\t(eg,\tnaproxen\t250\tmg\ttwice\tdaily)\tas\tfirst­line\tprophylactic\tthera­\npies,\twith\tstronger\tevidence\tsupporting\tuse\tof\tcolchicine.\tFor\tpatients\ton\tlong­term\t\nNSAID\t prophylaxis,\t a\t proton\t pump\t inhibitor\t or\t other\t acid­suppressing\t therapy\t is\t\nindicated\tto\tprotect\tfrom\tNSAID­induced\tgastric\tproblems.\t\n•\tLow­dose\t corticosteroid\t therapy\t (eg,\t prednisone\t ≤10\t mg/day)\t is\t an\t alternative\t for\t\npatients\twith\tintolerance,\tcontraindication,\tor\tlack\tof\tresponse\tto\tfirst­line\ttherapy.\t\nThe\t potential\t severe\t adverse\t effects\t of\t prolonged\t corticosteroid\t therapy\t preclude\t\ntheir\tuse\tas\tfirst­line\ttherapy.\n•\tContinue\tprophylaxis\tfor\tat\tleast\t6\tmonths\tor\t3\tmonths\tafter\tachieving\ttarget\tserum\t\nuric\t acid,\t whichever\t is\t longer.\t For\t patients\t with\t one\t or\t more\t tophi,\t continue\t pro­\nphylactic\ttherapy\tfor\t6\tmonths\tafter\tachieving\tthe\tserum\turate\ttarget\t(see\tFig.\t1–2).\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tCheck\tthe\tserum\turic\tacid\tlevel\tin\tpatients\tsuspected\tof\thaving\tan\tacute\tgout\tattack,\t\nparticularly\tif\tit\tis\tnot\tthe\tfirst\tattack,\tand\ta\tdecision\tis\tto\tbe\tmade\tabout\tstarting\tpro­\nphylaxis.\tHowever,\tacute\tgout\tcan\toccur\twith\tnormal\tserum\turic\tacid\tconcentrations.\n•\tMonitor\tpatients\twith\tacute\tgout\tfor\tsymptomatic\trelief\tof\tjoint\tpain,\tas\twell\tas\tpoten­\ntial\t adverse\t effects\t and\t drug\t interactions\t related\t to\t drug\t therapy.\t Acute\t pain\t of\t an\t\ninitial\t gout\t attack\t should\tbegin\t to\tease\t within\tabout\t8\thours\tof\ttreatment\t initiation.\t\t\nComplete\tresolution\tof\tpain,\terythema,\tand\tinflammation\tusually\toccurs\twithin\t48\tto\t\n72\thours.\n•\tFor\t patients\t receiving\t urate­lowering\t therapy,\t obtain\t baseline\t assessment\t of\t renal\t\nfunction,\thepatic\tenzymes,\tcomplete\tblood\tcount,\tand\telectrolytes.\tRecheck\tthe\ttests\t\nevery\t6\tto\t12\tmonths\tin\tpatients\treceiving\tlong­term\ttreatment.\n•\tDuring\t titration\t of\t urate­lowering\t therapy,\t monitor\t serum\t uric\t acid\t every\t 2\t to\t 5\t\nweeks;\tafter\tthe\turate\ttarget\tis\tachieved,\tmonitor\turic\tacid\tevery\t6\tmonths.\n•\tBecause\t of\t the\t high\t rates\t of\t comorbidities\t associated\t with\t gout\t (diabetes,\t chronic\t\nkidney\t disease,\t hypertension,\t obesity,\t myocardial\t infarction,\t heart\t failure,\t stroke),\t\nelevated\tserum\turic\tacid\tlevels\tor\tgout\tshould\tprompt\tevaluation\tfor\tcardiovascular\t\ndisease\t and\t the\t need\t for\t appropriate\t risk\t reduction\t measures.\t Clinicians\t should\t\nalso\tlook\tfor\tpossible\tcorrectable\tcauses\tof\thyperuricemia\t(eg,\tmedications,\tobesity,\t\nmalignancy,\talcohol\tabuse).\nSee Chapter 74, Gout and Hyperuricemia, authored by Michelle A.",
    "word_count": 424,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0033",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 33,
    "text": "  Bone and Joint Disorders\nANTIIFLAMMATORY PROPHYLAXIS DURING INITIATION  \nOF URATE-LOWERING THERAPY\n•\tInitiation\tof\turate­lowering\ttherapy\tcan\tprecipitate\tan\tacute\tgout\tattack\tdue\tto\tremod­\neling\t of\t urate\t crystal\t deposits\t in\t joints\t after\t rapid\t lowering\t of\t urate\t concentrations.\t\nProphylactic\tantiinflammatory\ttherapy\tshould\tbe\tused\tto\tprevent\tsuch\tgout\tattacks.\n•\tThe\tACR\tguidelines\trecommend\tlow­dose\toral\tcolchicine\t(0.6\tmg\ttwice\tdaily)\tand\t\nlow­dose\tNSAIDs\t(eg,\tnaproxen\t250\tmg\ttwice\tdaily)\tas\tfirst­line\tprophylactic\tthera­\npies,\twith\tstronger\tevidence\tsupporting\tuse\tof\tcolchicine.\tFor\tpatients\ton\tlong­term\t\nNSAID\t prophylaxis,\t a\t proton\t pump\t inhibitor\t or\t other\t acid­suppressing\t therapy\t is\t\nindicated\tto\tprotect\tfrom\tNSAID­induced\tgastric\tproblems.\t\n•\tLow­dose\t corticosteroid\t therapy\t (eg,\t prednisone\t ≤10\t mg/day)\t is\t an\t alternative\t for\t\npatients\twith\tintolerance,\tcontraindication,\tor\tlack\tof\tresponse\tto\tfirst­line\ttherapy.\t\nThe\t potential\t severe\t adverse\t effects\t of\t prolonged\t corticosteroid\t therapy\t preclude\t\ntheir\tuse\tas\tfirst­line\ttherapy.\n•\tContinue\tprophylaxis\tfor\tat\tleast\t6\tmonths\tor\t3\tmonths\tafter\tachieving\ttarget\tserum\t\nuric\t acid,\t whichever\t is\t longer.\t For\t patients\t with\t one\t or\t more\t tophi,\t continue\t pro­\nphylactic\ttherapy\tfor\t6\tmonths\tafter\tachieving\tthe\tserum\turate\ttarget\t(see\tFig.\t1–2).\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tCheck\tthe\tserum\turic\tacid\tlevel\tin\tpatients\tsuspected\tof\thaving\tan\tacute\tgout\tattack,\t\nparticularly\tif\tit\tis\tnot\tthe\tfirst\tattack,\tand\ta\tdecision\tis\tto\tbe\tmade\tabout\tstarting\tpro­\nphylaxis.\tHowever,\tacute\tgout\tcan\toccur\twith\tnormal\tserum\turic\tacid\tconcentrations.\n•\tMonitor\tpatients\twith\tacute\tgout\tfor\tsymptomatic\trelief\tof\tjoint\tpain,\tas\twell\tas\tpoten­\ntial\t adverse\t effects\t and\t drug\t interactions\t related\t to\t drug\t therapy.\t Acute\t pain\t of\t an\t\ninitial\t gout\t attack\t should\tbegin\t to\tease\t within\tabout\t8\thours\tof\ttreatment\t initiation.\t\t\nComplete\tresolution\tof\tpain,\terythema,\tand\tinflammation\tusually\toccurs\twithin\t48\tto\t\n72\thours.\n•\tFor\t patients\t receiving\t urate­lowering\t therapy,\t obtain\t baseline\t assessment\t of\t renal\t\nfunction,\thepatic\tenzymes,\tcomplete\tblood\tcount,\tand\telectrolytes.\tRecheck\tthe\ttests\t\nevery\t6\tto\t12\tmonths\tin\tpatients\treceiving\tlong­term\ttreatment.\n•\tDuring\t titration\t of\t urate­lowering\t therapy,\t monitor\t serum\t uric\t acid\t every\t 2\t to\t 5\t\nweeks;\tafter\tthe\turate\ttarget\tis\tachieved,\tmonitor\turic\tacid\tevery\t6\tmonths.\n•\tBecause\t of\t the\t high\t rates\t of\t comorbidities\t associated\t with\t gout\t (diabetes,\t chronic\t\nkidney\t disease,\t hypertension,\t obesity,\t myocardial\t infarction,\t heart\t failure,\t stroke),\t\nelevated\tserum\turic\tacid\tlevels\tor\tgout\tshould\tprompt\tevaluation\tfor\tcardiovascular\t\ndisease\t and\t the\t need\t for\t appropriate\t risk\t reduction\t measures.\t Clinicians\t should\t\nalso\tlook\tfor\tpossible\tcorrectable\tcauses\tof\thyperuricemia\t(eg,\tmedications,\tobesity,\t\nmalignancy,\talcohol\tabuse).\nSee Chapter 74, Gout and Hyperuricemia, authored by Michelle A. Fravel, Michael E.",
    "word_count": 424,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0034",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 34,
    "text": "Fravel, Michael E. \nErnst, and Elizabeth C. Clark, for a more detailed discussion of this topic.",
    "word_count": 16,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0035",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 35,
    "text": "9\nChapter_Title\n00\nChapter\n•\tOsteoarthritis\t (OA)\t is\t a\t common,\t progressive\t disorder\t affecting\t primarily\t weight-\t\nbearing\tdiarthrodial\tjoints,\tcharacterized\tby\tprogressive\tdeterioration\tand\tloss\tof\tarticu-\nlar\tcartilage,\tosteophyte\tformation,\tpain,\tlimitation\tof\tmotion,\tdeformity,\tand\tdisability.\t\nPATHOPHYSIOLOGY\n•\tPrimary (idiopathic) OA,\tthe\tmost\tcommon\ttype,\thas\tno\tknown\tcause.\t\n•\tSecondary OA\tis\tassociated\twith\ta\tknown\tcause,\tsuch\tas\ttrauma,\tmetabolic\tor\tendo-\ncrine\tdisorders,\tand\tcongenital\tfactors.\n•\tOA\t usually\t begins\t with\t damage\t to\t articular\t cartilage\t through\t injury,\t excessive\t joint\t\nloading\tfrom\tobesity\tor\tother\treasons,\tor\tjoint\tinstability\tor\tinjury.\tDamage\tto\tcartilage\t\nincreases\tactivity\tof\tchondrocytes\tin\tattempt\tto\trepair\tdamage,\tleading\tto\tincreased\tsyn-\nthesis\tof\tmatrix\tconstituents\twith\tcartilage\tswelling.\tNormal\tbalance\tbetween\t\tcartilage\t\nbreakdown\tand\tresynthesis\tis\tlost,\twith\tincreasing\tdestruction\tand\tcartilage\tloss.\n•\tSubchondral\t bone\t adjacent\t to\t articular\t cartilage\t undergoes\t pathologic\t changes\t and\t\nreleases\tvasoactive\tpeptides\tand\tmatrix\tmetalloproteinases\t(MMPs).\tNeovascularization\t\nand\t increased\t permeability\t of\t adjacent\t cartilage\t occur,\t which\t contribute\t to\t cartilage\t\nloss\tand\tchondrocyte\tapoptosis.\n•\tCartilage\tloss\tcauses\tjoint\tspace\tnarrowing\tand\tpainful,\tdeformed\tjoints.\tRemaining\t\ncartilage\t softens\t and\t develops\t fibrillations,\t followed\t by\t further\t cartilage\t loss\t and\t\nexposure\t of\t underlying\t bone.\tNew\t bone\tformations\t (osteophytes)\t at\t joint\tmargins\t\ndistant\tfrom\tcartilage\tdestruction\tare\tthought\tto\thelp\tstabilize\taffected\tjoints.\n•\tInflammatory\tchanges\tcan\toccur\tin\tthe\tjoint\tcapsule\tand\tsynovium.\tCrystals\tor\tcar-\ntilage\tshards\tin\tsynovial\tfluid\tmay\tcontribute\tto\tinflammation.\tInterleukin-1,\tprosta-\nglandin\tE2,\ttumor\tnecrosis\tfactor-α\t(TNF-α),\tand\tnitric\toxide\tin\tsynovial\tfluid\tmay\t\nalso\tplay\ta\trole.\tInflammatory\tchanges\tresult\tin\tsynovial\teffusions\tand\tthickening.\n•\tPain\tmay\tresult\tfrom\tdistention\tof\tthe\tsynovial\tcapsule\tby\tincreased\tjoint\tfluid;\tmicro-\nfracture;\tperiosteal\tirritation;\tor\tdamage\tto\tligaments,\tsynovium,\tor\tthe\tmeniscus.\nCLINICAL PRESENTATION\n•\tRisk\t factors\t include\t increasing\t age,\t obesity,\t repetitive\t use\t through\t work\t or\t leisure\t\nactivities,\tjoint\ttrauma,\tand\tgenetic\tpredisposition.\n•\tPredominant\tsymptom\tis\tdeep,\taching\tpain\tin\taffected\tjoints.\tPain\taccompanies\tjoint\t\nactivity\tand\tdecreases\twith\trest.\n•\tJoints\t most\t commonly\t affected\t are\t the\t distal\t interphalangeal\t (DIP)\t and\t proximal\t\ninterphalangeal\t (PIP)\t joints\t of\t the\t hand,\t first\t carpometacarpal\t joint,\t knees,\t hips,\t\ncervical\tand\tlumbar\tspine,\tand\tfirst\tmetatarsophalangeal\t(MTP)\tjoint\tof\tthe\ttoe.\n•\tLimitation\t of\t motion,\t stiffness,\t crepitus,\t and\t deformities\t may\t occur.\t Patients\t with\t\nlower\textremity\tinvolvement\tmay\treport\tweakness\tor\tinstability.\n•\tUpon\tarising,\tjoint\tstiffness\ttypically\tlasts\tless\tthan\t30\tminutes\tand\tresolves\twith\tmotion.\n•\tPresence\tof\twarm,\tred,\tand\ttender\tjoints\tsuggests\tinflammatory\tsynovitis.\n•\tPhysical\t examination\t of\t affected\t joints\t reveals\t tenderness,\t crepitus,\t and\t possibly\t\nenlargement.\tHeberden\tand\tBouchard\tnodes\tare\tbony\tenlargements\t(osteophytes)\tof\t\nthe\tDIP\tand\tPIP\tjoints,\trespectively.\nDIAGNOSIS\n•\tDiagnosis\tis\tmade\tthrough\tpatient\thistory,\tphysician\texamination,\tradiologic\tfind-\nings,\tand\tlaboratory\ttesting.\n•\tAmerican\t College\t of\t Rheumatology\t (ACR)\t criteria\t for\t classification\t of\t OA\t of\t the\t\nhips,\t knees,\t and\t hands\t include\t presence\t of\t pain,\t bony\t changes\t on\t examination,\t\nOsteoarthritis\n2\nC h a p t e r",
    "word_count": 484,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0036",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 36,
    "text": "10\nSeCt ION 1     Bone and Joint Disorders\nnormal\terythrocyte\tsedimentation\trate\t(ESR),\tand\tradiographs\tshowing\tosteophytes\t\nor\tjoint\tspace\tnarrowing.\n•\tFor\thip\tOA,\tpatient\tmust\thave\thip\tpain\tand\ttwo\tof\tthe\tfollowing:\t(1)\tESR\tless\tthan\t\t\n20\tmm/h,\t(2)\tradiographic\tfemoral\tor\tacetabular\tosteophytes,\tand/or\t(3)\tradiographic\t\njoint\tspace\tnarrowing.\n•\tFor\tknee\tOA,\tpatient\tmust\thave\tknee\tpain\tand\tradiographic\tosteophytes\tin\taddition\t\nto\tone\tor\tmore\tof\tthe\tfollowing:\t(1)\t age\tmore\tthan\t50\tyears,\t(2)\tmorning\tstiffness\t\nlasting\t 30\t minutes\t or\t less,\t(3)\t crepitus\t on\t motion,\t (4)\t bony\t enlargement,\t(6)\t bony\t\ntenderness,\tand/or\t(7)\tpalpable\tjoint\twarmth.\n•\tESR\tmay\tbe\tslightly\televated\tif\tinflammation\tis\tpresent.\tRheumatoid\tfactor\tis\tnegative.\t\nAnalysis\t of\t synovial\t fluid\t reveals\t high\t viscosity\t and\t mild\t leukocytosis\t (<2000\t white\t\nblood\tcells/mm3\t[<2\t×\t109/L])\twith\tpredominantly\tmononuclear\tcells.\nTREATMENT\n•\tGoals\tof\tTreatment:\t(1)\teducate\tpatient,\tfamily\tmembers,\tand\tcaregivers;\t(2)\trelieve\t\npain\tand\tstiffness;\t(3)\tmaintain\tor\timprove\tjoint\tmobility;\t(4)\tlimit\tfunctional\timpair-\nment;\tand\t(5)\tmaintain\tor\timprove\tquality\tof\tlife.\nNONPHARMACOLOGIC THERAPY\n•\tEducate\tpatient\tabout\tdisease\tprocess\tand\textent,\tprognosis,\tand\ttreatment.\tPromote\t\ndietary\tcounseling,\texercise,\tand\tweight\tloss\tprogram\tfor\toverweight\tpatients.\n•\tPhysical\t therapy—with\t heat\t or\t cold\t treatments\t and\t an\t exercise\t program—helps\t\nmaintain\trange\tof\tmotion\tand\treduce\tpain\tand\tneed\tfor\tanalgesics.\n•\tAssistive\tand\torthotic\tdevices\t(canes,\twalkers,\tbraces,\theel\tcups,\tinsoles)\tcan\tbe\tused\t\nduring\texercise\tor\tdaily\tactivities.\n•\tSurgical\tprocedures\t(eg,\tosteotomy,\tarthroplasty,\tjoint\tfusion)\tare\tindicated\tfor\tfunc-\ntional\tdisability\tand/or\tsevere\tpain\tunresponsive\tto\tconservative\ttherapy.\nPHARMACOLOGIC THERAPY (T Ab LE 2–1)\nGeneral Approach\n•\tDrug\t therapy\t is\t targeted\t at\t relief\t of\t pain.\t A\t conservative\t approach\t is\t warranted\t\nbecause\tOA\toften\toccurs\tin\tolder\tindividuals\twith\tother\tmedical\tconditions.\n•\tApply\tan\tindividualized\tapproach\t(Figs.",
    "word_count": 299,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0037",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 37,
    "text": "  Bone and Joint Disorders\nnormal\terythrocyte\tsedimentation\trate\t(ESR),\tand\tradiographs\tshowing\tosteophytes\t\nor\tjoint\tspace\tnarrowing.\n•\tFor\thip\tOA,\tpatient\tmust\thave\thip\tpain\tand\ttwo\tof\tthe\tfollowing:\t(1)\tESR\tless\tthan\t\t\n20\tmm/h,\t(2)\tradiographic\tfemoral\tor\tacetabular\tosteophytes,\tand/or\t(3)\tradiographic\t\njoint\tspace\tnarrowing.\n•\tFor\tknee\tOA,\tpatient\tmust\thave\tknee\tpain\tand\tradiographic\tosteophytes\tin\taddition\t\nto\tone\tor\tmore\tof\tthe\tfollowing:\t(1)\t age\tmore\tthan\t50\tyears,\t(2)\tmorning\tstiffness\t\nlasting\t 30\t minutes\t or\t less,\t(3)\t crepitus\t on\t motion,\t (4)\t bony\t enlargement,\t(6)\t bony\t\ntenderness,\tand/or\t(7)\tpalpable\tjoint\twarmth.\n•\tESR\tmay\tbe\tslightly\televated\tif\tinflammation\tis\tpresent.\tRheumatoid\tfactor\tis\tnegative.\t\nAnalysis\t of\t synovial\t fluid\t reveals\t high\t viscosity\t and\t mild\t leukocytosis\t (<2000\t white\t\nblood\tcells/mm3\t[<2\t×\t109/L])\twith\tpredominantly\tmononuclear\tcells.\nTREATMENT\n•\tGoals\tof\tTreatment:\t(1)\teducate\tpatient,\tfamily\tmembers,\tand\tcaregivers;\t(2)\trelieve\t\npain\tand\tstiffness;\t(3)\tmaintain\tor\timprove\tjoint\tmobility;\t(4)\tlimit\tfunctional\timpair-\nment;\tand\t(5)\tmaintain\tor\timprove\tquality\tof\tlife.\nNONPHARMACOLOGIC THERAPY\n•\tEducate\tpatient\tabout\tdisease\tprocess\tand\textent,\tprognosis,\tand\ttreatment.\tPromote\t\ndietary\tcounseling,\texercise,\tand\tweight\tloss\tprogram\tfor\toverweight\tpatients.\n•\tPhysical\t therapy—with\t heat\t or\t cold\t treatments\t and\t an\t exercise\t program—helps\t\nmaintain\trange\tof\tmotion\tand\treduce\tpain\tand\tneed\tfor\tanalgesics.\n•\tAssistive\tand\torthotic\tdevices\t(canes,\twalkers,\tbraces,\theel\tcups,\tinsoles)\tcan\tbe\tused\t\nduring\texercise\tor\tdaily\tactivities.\n•\tSurgical\tprocedures\t(eg,\tosteotomy,\tarthroplasty,\tjoint\tfusion)\tare\tindicated\tfor\tfunc-\ntional\tdisability\tand/or\tsevere\tpain\tunresponsive\tto\tconservative\ttherapy.\nPHARMACOLOGIC THERAPY (T Ab LE 2–1)\nGeneral Approach\n•\tDrug\t therapy\t is\t targeted\t at\t relief\t of\t pain.\t A\t conservative\t approach\t is\t warranted\t\nbecause\tOA\toften\toccurs\tin\tolder\tindividuals\twith\tother\tmedical\tconditions.\n•\tApply\tan\tindividualized\tapproach\t(Figs. 2–1 and 2–2).\tContinue\tappropriate\tnon-\ndrug\ttherapies\twhen\tinitiating\tdrug\ttherapy.\nKnee and Hip OA\n•\tAcetaminophen\tis\ta\tpreferred\tfirst-line\ttreatment;\tit\tmay\tbe\tless\teffective\tthan\toral\t\nnonsteroidal\tanti-inflammatory\tdrugs\t(NSAIDs)\tbut\thas\tless\trisk\tof\tserious\tgastroin-\ntestinal\t(GI)\tand\tcardiovascular\tevents.\n•\tIf\ta\tpatient\tfails\tacetaminophen,\tnonselective NSAIDs or cyclooxygenase-2 (COX-2) \nselective inhibitors (eg,\t celecoxib)\t are\t recommended.\t COX-2\t inhibitors\t pose\t less\t\nrisk\tfor\tadverse\tGI\tevents\tthan\tnonselective\tNSAIDs,\tbut\tthis\tadvantage\tmay\tnot\tbe\t\nsustained\t beyond\t6\t months\t and\tis\t substantially\treduced\tfor\t patients\t taking\taspirin.\t\nProton\tpump\tinhibitors\t(PPIs)\tand\tmisoprostol\treduce\tadverse\tGI\tevents\tin\tpatients\t\ntaking\tNSAIDs.\n•\tFor\t knee\t OA,\t topical NSAIDs \t are\t recommended\t if\t acetaminophen\t fails\t and\t are\t\npreferred\tover\toral\tNSAIDs\tin\tpatients\tolder\tthan\t75\tyears.\tT opical\tNSAIDs\tprovide\t\nsimilar\tpain\trelief\twith\tfewer\tadverse\tGI\tevents\tthan\toral\tNSAIDs\tbut\tmay\tbe\tassoci-\nated\twith\tadverse\tevents\tat\tthe\tapplication\tsite.\n•\tIntra-articular (IA) corticosteroid injections \t are\t recommended\t for\t both\t hip\t and\t\nknee\tOA\twhen\tanalgesia\twith\tacetaminophen\tor\tNSAIDs\tis\tsuboptimal.\tInjections\t\ncan\t be\t given\t with\t concomitant\t oral\t analgesics\t for\t additional\t pain\t control.\t Do\t\nnot\t administer\t injections\t more\t frequently\t than\t once\t every\t 3\t months\t to\t minimize\t\n\tsystemic\tadverse\teffects.",
    "word_count": 501,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0038",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 38,
    "text": "11\nOsteoarthritis  |  Chapter  2\n TABLE 2–1  Medications for the Treatment of Osteoarthritis\nDrug Starting Dose Usual Range\nOral analgesics\nAcetaminophen 325–500 mg 3 times \na day\n325–650 mg every 4–6 h or 1 g 3–4 times/\nday\nTramadol 25 mg in the morning Titrate dose in 25-mg increments to reach a  \nmaintenance dose of 50–100 mg 3 times \na day.\nTramadol ER 100 mg daily Titrate to 200–300 mg daily\nHydrocodone/ \nacetaminophen\n5 mg/325 mg 3 times \ndaily\n2.5–10 mg/325–650 mg 3–5 times daily\nOxycodone/ \nacetaminophen\n5 mg/325 mg 3 times \ndaily\n2.5–10 mg/325–650 mg 3–5 times daily\nTopical analgesics\nCapsaicin 0.025% or \n0.075%\nApply to affected joint 3–4 times per day.\nDiclofenac 1% gel Apply 2 or 4 g per site as prescribed, 4 \ntimes daily.\nDiclofenac 1.3% \npatch\nApply one patch twice daily to the site to \nbe treated, as directed. \nDiclofenac 1.5% \nsolution\nApply 40 drops to the affected knee, apply -\ning and rubbing in 10 drops at a time. \nRepeat for a total of 4 times daily.\nIntra-articular cortico-\nsteroids\nTriamcinolone 5–15 mg per joint 10–40 mg per large joint (knee, hip, shoul-\nder)\nMethylprednisolone \nacetate\n10–20 mg per joint 20–80 mg per large joint (knee, hip, shoul-\nder) \nNSAIDs\nAspirin (plain, buff-\nered, or enteric-\ncoated)\n325 mg 3 times a day 325–650 mg 4 times a day\nCelecoxib 100 mg daily 100 mg twice daily or 200 mg daily\nDiclofenac IR 50 mg twice a day 50–75 mg twice a day\nDiclofenac XR 100 mg daily 100–200 mg daily\nDiflunisal 250 mg twice a day 500–750 mg twice a day\nEtodolac 300 mg twice a day 400 to 500 mg twice a day\nFenoprofen 400 mg 3 times a day 400–600 mg 3–4 times a day\nFlurbiprofen 100 mg twice a day 200–300 mg/day in 2–4 divided doses\nIbuprofen 200 mg 3 times a day 1200–3200 mg/day in 3–4 divided doses\nIndomethacin 25 mg twice a day Titrate dose by 25–50 mg/day until pain  \ncontrolled or maximum dose of 50 mg  \n3 times a day\n(continued)",
    "word_count": 344,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0039",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 39,
    "text": "12\nSeCt ION 1  |  Bone and Joint Disorders\n TABLE 2–1   Medications for the Treatment of Osteoarthritis (Continued)\nDrug Starting Dose Usual Range\nIndomethacin SR 75 mg SR once daily Can titrate to 75 mg SR twice daily if \nneeded\nKetoprofen 50 mg 3 times a day 50–75 mg 3–4 times a day\nMeclofenamate 50 mg 3 times a day 50–100 mg 3–4 times a day\nMefenamic acid 250 mg 3 times a day 250 mg 4 times a day\nMeloxicam 7.5 mg daily 15 mg daily\nNabumetone 500 mg daily 500–1000 mg 1–2 times a day\nNaproxen 250 mg twice a day 500 mg twice a day\nNaproxen sodium 220 mg twice a day 220–550 mg twice a day\nNaproxen sodium CR 750–1000 mg once \ndaily\n500–1500 mg once daily \nOxaprozin 600 mg daily 600–1200 mg daily\nPiroxicam 10 mg daily 20 mg daily\nSalsalate 500 mg twice a day 500–1000 mg 2–3 times a day\nCR, controlled-release; ER, extended-release; IR, immediate-release; SR, sustained-release; XR, \nextended-release.\nPatient requires\npharmacologic treatment\n Is acetaminophen\ncontraindicated?\nAcetaminophena\nMaximum 4 g/day\nContinue treatment\nNote: Selection of a medication should consider patient-specific characteristics.\naThe patient must be counseled regarding all acetaminophen-containing products.\nbWhen used for chronic management of OA, consider addition of a proton pump inhibitor.\nIs treatment effective?\nNo Yes\nseYoN\nAlternative second-line\nagents\n• Opioid analgesics\n• Surgery\n• Duloxetine (knee only)\n• Intra-articular hyaluronan\nAlternative /f_irst-line\nagents\n• Topical NSAIDs\n (knee only)\n• Intra-articular\n c orticosteroids\n• Tramadol\n• Oral NSAIDs\n (if <75 years or\n low CV and GI risk)b \nFIGURE 2–1.  Treatment recommendations for hip and knee osteoarthritis (OA). \n(CV, cardiovascular; GI, gastrointestinal; NSa ID, nonsteroidal anti-inflammatory drug.)",
    "word_count": 278,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0040",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 40,
    "text": "13\nOsteoarthritis  |  Chapter  2\n•\tTramadol\tis\trecommended\tfor\thip\tand\tknee\tOA\tin\tpatients\twho\thave\tfailed\tsched-\nuled\tfull-dose\tacetaminophen\tand\ttopical\tNSAIDs,\twho\tare\tnot\tappropriate\tcandi-\ndates\tfor\toral\tNSAIDs,\tand\twho\tare\tnot\table\tto\treceive\tIA\tcorticosteroids.\tTramadol\t\ncan\tbe\tadded\tto\tpartially\teffective\tacetaminophen\tor\toral\tNSAID\ttherapy.\n•\tOpioids\tshould\tbe\tconsidered\tin\tpatients\tnot\tresponding\tadequately\tto\tnonpharma-\ncologic\tand\tfirst-line\tpharmacologic\ttherapies.\tPatients\twho\tare\tat\thigh\tsurgical\trisk\t\nand\tcannot\tundergo\tjoint\tarthroplasty\tare\talso\tcandidates\tfor\topioid\ttherapy.\tAdverse\t\nevents\tlimit\troutine\tuse\tof\topioids\tfor\ttreatment\tof\tOA\tpain.\n•\tDuloxetine\tcan\tbe\tused\tas\tadjunctive\ttreatment\tin\tpatients\twith\tpartial\tresponse\tto\t\nfirst-line\tanalgesics\t(acetaminophen,\toral\tNSAIDs).\tIt\tmay\tbe\ta\tpreferred\tsecond-line\t\nmedication\tin\tpatients\twith\tboth\tneuropathic\tand\tmusculoskeletal\tOA\tpain.\t\n•\tIA hyaluronic acid\tis\tnot\troutinely\trecommended\tfor\tknee\tOA\tpain.\tInjections\tdo\t\nnot\tprovide\tclinically\tmeaningful\timprovement\tand\tmay\tbe\tassociated\twith\tserious\t\nadverse\tevents\t(eg,\tincreased\tpain,\tjoint\tswelling,\tand\tstiffness).\t\n•\tGlucosamine and/or chondroitin and topical rubefacients ( eg, methyl salicy-\nlate, trolamine salicylate) \tlack\tuniform\tefficacy\tfor\thip\tand\tknee\tpain\tand\tare\tnot\t\n\tpreferred\ttreatment\toptions.\nPatient requires\npharmacologic treatment\nIs patient ≥75 years of\nage?\naSelection of a medication should consider patient-specific characteristics\nbWhen used for chronic management of OA, consider addition of a proton pump inhibitor\ncShould not combine topical NSAIDs and oral NSAIDs\nseYoN\noNoN\nFirst-line agents\nTopical NSAIDs \nor\nTopical capsaicin\nand/or\nTramadol\nFirst-line Agents\nOral NSAIDsb (if\nlow CV and GI risk) \nTopical NSAIDs\nor\nTopical capsaicin\nand/or\nTramadol\nAlternative regimens\nCombined therapy\nwith 2 first-line\nagentsc\nAlternative Regimens\nCombined therapy\nwith 2 first-line\nagentsc\n(ie, oral NSAIDs\nand topical capsaicin\nor tramadol)\nIs treatment\neffective?\nIs treatment\neffective?Continue treatment YesYes\nFIGURE 2–2.  Treatment recommendations for hand osteoarthritis (OA). (CV, car-\ndiovascular; GI, gastrointestinal; NSa ID, nonsteroidal anti-inflammatory drug.)",
    "word_count": 318,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0041",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 41,
    "text": "14\nSeCt ION 1  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0042",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 42,
    "text": "14\nSeCt ION 1     Bone and Joint Disorders\nHand OA\n•\tTopical NSAIDs are\ta\tfirst-line\toption\tfor\thand\tOA.\tDiclofenac\thas\tefficacy\tsimilar\t\nto\toral\tibuprofen\tand\toral\tdiclofenac\twith\tfewer\tadverse\tGI\tevents,\talbeit\twith\tsome\t\nlocal\tapplication\tsite\tevents.\n•\tOral NSAIDs are\tan\talternative\tfirst-line\ttreatment\tfor\tpatients\twho\tcannot\ttolerate\t\nthe\tlocal\tskin\treactions\tor\twho\treceived\tinadequate\trelief\tfrom\ttopical\tNSAIDs.\n•\tCapsaicin cream is\t an\t alternative\t first-line\t treatment\t and\t demonstrates\t modest\t\nimprovement\tin\tpain\tscores.\tIt\tis\ta\treasonable\toption\tfor\tpatients\tunable\tto\ttake\toral\t\nNSAIDs.\tAdverse\teffects\tare\tprimarily\tskin\tirritation\tand\tburning.\t\n•\tTramadol\tis\tan\talternative\tfirst-line\ttreatment\tand\tis\ta\treasonable\tchoice\tfor\tpatients\t\nwho\t do\t not\t respond\t to\t topical\t therapy\t and\t are\t not\t candidates\t for\t oral\t NSAIDs\t\nbecause\t of\t high\t GI,\t cardiovascular,\t or\t renal\t risks.\t Tramadol\t may\t also\t be\t used\t in\t\ncombination\twith\tpartially\teffective\tacetaminophen,\ttopical\ttherapy,\tor\toral\tNSAIDs.\nDrug Class Information\n•\tAcetaminophen\t is\t usually\t well\t tolerated,\t but\t potentially\t fatal\t hepatotoxicity\t with\t\noverdose\t is\t well\t documented.\t Avoid\t in\t chronic\t alcohol\t users\t or\t patients\t with\t\nliver\t disease.\t Renal\t toxicity\t is\t possible\t with\t long-term\t use;\t use\t of\t nonprescription\t\ncombination\t products\t containing\t acetaminophen\t and\t NSAIDs\t is\t discouraged\t\nbecause\tof\tincreased\trisk\tof\trenal\tfailure.\n•\tNSAIDs\tcause\tminor\tGI\tcomplaints\tsuch\tas\tnausea,\tdyspepsia,\tanorexia,\tabdominal\t\npain,\t flatulence,\t and\t diarrhea\t in\t 10%\t to\t 60%\t of\t patients.\t They\t may\t cause\t gastric\t\nand\t duodenal\t ulcers\t and\t bleeding\t through\t direct\t (topical)\t or\t indirect\t (systemic)\t\nmechanisms.\tRisk\tfactors\tfor\tNSAID-associated\tulcers\tand\tulcer\tcomplications\t(per-\nforation,\tgastric\toutlet\tobstruction,\tand\tGI\tbleeding)\tinclude\thistory\tof\tcomplicated\t\nulcer,\t concomitant\t use\t of\t multiple\t NSAIDs\t (including\t aspirin)\t or\t anticoagulants,\t\nuse\t of\t high-dose\t NSAIDs,\t and\t age\t more\t than\t 70\t years.\t Options\t for\t reducing\t the\t\nGI\trisk\tof\tnonselective\tNSAIDs\tinclude\tusing\t(1)\tthe\tlowest\tdose\tpossible\tand\tonly\t\nwhen\t needed,\t (2)\t misoprostol\t four\t times\t daily\t with\t the\t NSAID,\t (3)\t a\t PPI\t or\t full-\ndose\t H2-receptor\tantagonist\tdaily\twith\tthe\t NSAID.\t COX-2\tselective\tinhibitors\t (eg,\t\ncelecoxib)\t may\t reduce\t risk\t of\t GI\t events\t but\t increase\t risk\t of\t cardiovascular\t events.\t\nNSAIDs\t may\t also\t cause\t kidney\t diseases,\t hepatitis,\t hypersensitivity\t reactions,\t rash,\t\nand\tCNS\tcomplaints\tof\tdrowsiness,\tdizziness,\theadaches,\tdepression,\tconfusion,\tand\t\ntinnitus.\tAll\tnonselective\tNSAIDs\tinhibit\tCOX-1–dependent\tthromboxane\tproduc-\ntion\tin\tplatelets,\tthereby\tincreasing\tbleeding\trisk.\tAvoid\tNSAIDs\tin\tlate\tpregnancy\t\nbecause\tof\trisk\tof\tpremature\tclosure\tof\tductus\tarteriosus.\tThe\tmost\tpotentially\tseri-\nous\tdrug\tinteractions\tinclude\tuse\tof\tNSAIDs\twith\tlithium,\twarfarin,\toral\thypogly-\ncemics,\tmethotrexate,\tantihypertensives,\tangiotensin-converting\tenzyme\tinhibitors,\t\nβ-blockers,\tand\tdiuretics.\n•\tT opical\t NSAIDs\t are\t associated\t with\t fewer\t GI\t and\t other\t adverse\t events\t than\t oral\t\nNSAIDs\t except\t for\t local\t application\t site\t reactions\t (eg,\t dry\t skin,\t pruritus,\t rash).\t\nPatients\tusing\ttopical\tproducts\tshould\tavoid\toral\tNSAIDs\tto\tminimize\tthe\tpotential\t\nfor\tadditive\tside\teffects.\n•\tIA\tcorticosteroids\tcan\tprovide\texcellent\tpain\trelief,\tparticularly\twhen\tjoint\teffusion\t\nis\tpresent.\tAfter\taseptic\taspiration\tof\tthe\teffusion\tand\tcorticosteroid\tinjection,\tinitial\t\npain\t relief\t may\t occur\t within\t 24\t to\t 72\t hours,\t with\t peak\t relief\t occurring\t after\t 7\t to\t\t\n10\t days\t and\t lasting\t for\t 4\t to\t 8\t weeks.\t Local\t adverse\t effects\t can\t include\t infection,\t\nosteonecrosis,\ttendon\trupture,\tand\tskin\tatrophy\tat\tthe\tinjection\tsite.\tSystemic\tcorti-\ncosteroid\ttherapy\tis\tnot\trecommended\tin\tOA,\tgiven\tlack\tof\tproven\tbenefit\tand\twell-\nknown\tadverse\teffects\twith\tlong-term\tuse.\n•\tCapsaicin\tmust\tbe\tused\tregularly\tto\tbe\teffective,\tand\tit\tmay\trequire\tup\tto\t2\tweeks\tto\t\ntake\teffect.\tAdverse\teffects\tare\tprimarily\tlocal\twith\tone\tthird\tof\tpatients\texperiencing\t\nburning,\tstinging,\tand/or\terythema\tthat\tusually\tsubsides\twith\trepeated\tapplication.\t\nW arn\tpatients\tnot\tto\tget\tcream\tin\ttheir\teyes\tor\tmouth\tand\tto\twash\thands\tafter\tappli-\ncation.\tApplication\tof\tthe\tcream,\tgel,\tor\tlotion\tis\trecommended\tfour\ttimes\tdaily,\tbut\t\ntwice-daily\tapplication\tmay\tenhance\tlong-term\tadherence\twith\tadequate\tpain\trelief.",
    "word_count": 629,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0043",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 43,
    "text": "15\nOsteoarthritis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0044",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 44,
    "text": "15\nOsteoarthritis     Chapter  2\n•\tTramadol\tis\tassociated\twith\topioid-like\tadverse\teffects\tsuch\tas\tnausea,\tvomiting,\tdiz-\nziness,\tconstipation,\theadache,\tand\tsomnolence.\tHowever,\ttramadol\tis\tnot\tassociated\t\nwith\t life-threatening\t GI\tbleeding,\t cardiovascular\tevents,\t or\trenal\t failure.\tThe\tmost\t\nserious\tadverse\tevent\tis\tseizures.\tAlthough\tnot\tclassified\tas\ta\tcontrolled\tsubstance,\t\ndrug-seeking\tbehaviors\thave\tbeen\treported\twith\ttramadol\tuse.\tThere\tis\tincreased\trisk\t\nof\tserotonin\tsyndrome\twhen\ttramadol\tis\tused\twith\tother\tserotonergic\tmedications,\t\nincluding\tduloxetine.\n•\tStart\t opioid\t analgesics\t in\t low\t doses,\t allowing\t a\t sufficient\t duration\t between\t dose\t\nincreases\t to\t assess\t efficacy\t and\t safety.\t Sustained-release\t compounds\t usually\t offer\t\nbetter\t pain\t control\t throughout\t the\t day.\t Common\t adverse\t effects\t include\t nausea,\t\nsomnolence,\tconstipation,\tdry\tmouth,\tand\tdizziness.\tOpioid\tdependence,\taddiction,\t\ntolerance,\t hyperalgesia,\t and\t issues\t surrounding\t drug\t diversion\t may\t be\t associated\t\nwith\tlong-term\ttreatment.\n•\tDuloxetine\t may\t cause\t nausea,\t dry\t mouth,\t constipation,\t anorexia,\t fatigue,\t somno-\nlence,\tand\tdizziness.\tSerious\trare\tevents\tinclude\tStevens-Johnson\tsyndrome\tand\tliver\t\nfailure.\tConcomitant\tuse\twith\tother\tmedications\tthat\tincrease\tserotonin\tconcentra-\ntion\t(including\ttramadol)\tincreases\trisk\tof\tserotonin\tsyndrome.\n•\tHyaluronic\t acid\t (sodium\t hyaluronate)\t injections\t have\t limited\t benefit\t for\t patients\t\nwith\tknee\tOA\tand\thave\tnot\tbeen\tshown\tto\tbenefit\tpatients\twith\thip\tOA.\tInjections\t\nare\twell\ttolerated,\tbut\tacute\tjoint\tswelling,\teffusion,\tand\tstiffness,\tas\twell\tas\tlocal\tskin\t\nreactions\t(eg,\trash,\tecchymoses,\tor\tpruritus)\thave\tbeen\treported.\tSix\tintra-articular\t\npreparations\tand\tregimens\tare\tavailable\tfor\tOA\tknee\tpain:\n✓\tSodium hyaluronate 20 mg/2 mL\t(Hyalgan)\tonce\tweekly\tfor\tfive\tinjections\n✓\tSodium hyaluronate 20 mg/2 mL\t(Euflexxa)\tonce\tweekly\tfor\tthree\tinjections\n✓\tSodium hyaluronate 25 mg/2.5 mL\t(Supartz)\tonce\tweekly\tfor\tfive\tinjections\n✓\tHylan polymers 16 mg/2 mL\t(Synvisc)\tonce\tweekly\tfor\tthree\tinjections\n✓\t\tHylan polymers 48 mg/6 mL \t (Synvisc-One)\t single\t injection\t (with\t efficacy\t for\t\nup\tto\t26\tweeks)\n✓\tHyaluronan 30 mg/2 mL\t(Orthovisc)\tonce\tweekly\tfor\tthree\tinjections\n•\tGlucosamine\tadverse\teffects\tare\tmild\tand\tinclude\tflatulence,\tbloating,\tand\tabdominal\t\ncramps;\t do\t not\t use\t in\t patients\t with\t shellfish\t allergies.\t The\t most\t common\t adverse\t\neffect\tof\tchondroitin\tis\tnausea.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tT o\tmonitor\tefficacy,\tassess\tbaseline\tpain\twith\ta\tvisual\tanalog\tscale,\tand\tassess\trange\t\nof\tmotion\tfor\taffected\tjoints\twith\tflexion,\textension,\tabduction,\tor\tadduction.\n•\tDepending\ton\tthe\tjoint(s)\taffected,\tmeasurement\tof\tgrip\tstrength\tand\t50-ft\twalking\t\ntime\tcan\thelp\tassess\thand\tand\thip/knee\tOA,\trespectively.\n•\tBaseline\t radiographs\tcan\t document\textent\tof\t joint\tinvolvement\tand\t follow\tdisease\t\nprogression\twith\ttherapy.\n•\tOther\t measures\t include\t the\t clinician’ s\t global\tassessment\t based\ton\t patient’ s\t history\t\nof\t activities\t and\t limitations\t caused\t by\t OA,\t the\t W estern\t Ontario\t and\t McMaster\t\nUniversities\tArthrosis\tIndex,\tStanford\tHealth\tAssessment\tQuestionnaire,\tand\tdocu-\nmentation\tof\tanalgesic\tor\tNSAID\tuse.\n•\tAsk\t patients\t about\t adverse\t effects\t from\t medications.\t Monitor\t for\t signs\t of\t drug-\nrelated\teffects,\tsuch\tas\tskin\trash,\theadaches,\tdrowsiness,\tweight\tgain,\tor\thypertension\t\nfrom\tNSAIDs.\n•\tObtain\tbaseline\tserum\tcreatinine,\thematology\tprofile,\tand\tserum\ttransaminases\twith\t\nrepeat\tlevels\tat\t6-\tto\t12-month\tintervals\tto\tidentify\tspecific\ttoxicities\tto\tthe\tkidney,\t\nliver,\tGI\ttract,\tor\tbone\tmarrow.\nSee Chapter 71, Osteoarthritis, authored by Lucinda M.",
    "word_count": 513,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0045",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 45,
    "text": "  Chapter  2\n•\tTramadol\tis\tassociated\twith\topioid-like\tadverse\teffects\tsuch\tas\tnausea,\tvomiting,\tdiz-\nziness,\tconstipation,\theadache,\tand\tsomnolence.\tHowever,\ttramadol\tis\tnot\tassociated\t\nwith\t life-threatening\t GI\tbleeding,\t cardiovascular\tevents,\t or\trenal\t failure.\tThe\tmost\t\nserious\tadverse\tevent\tis\tseizures.\tAlthough\tnot\tclassified\tas\ta\tcontrolled\tsubstance,\t\ndrug-seeking\tbehaviors\thave\tbeen\treported\twith\ttramadol\tuse.\tThere\tis\tincreased\trisk\t\nof\tserotonin\tsyndrome\twhen\ttramadol\tis\tused\twith\tother\tserotonergic\tmedications,\t\nincluding\tduloxetine.\n•\tStart\t opioid\t analgesics\t in\t low\t doses,\t allowing\t a\t sufficient\t duration\t between\t dose\t\nincreases\t to\t assess\t efficacy\t and\t safety.\t Sustained-release\t compounds\t usually\t offer\t\nbetter\t pain\t control\t throughout\t the\t day.\t Common\t adverse\t effects\t include\t nausea,\t\nsomnolence,\tconstipation,\tdry\tmouth,\tand\tdizziness.\tOpioid\tdependence,\taddiction,\t\ntolerance,\t hyperalgesia,\t and\t issues\t surrounding\t drug\t diversion\t may\t be\t associated\t\nwith\tlong-term\ttreatment.\n•\tDuloxetine\t may\t cause\t nausea,\t dry\t mouth,\t constipation,\t anorexia,\t fatigue,\t somno-\nlence,\tand\tdizziness.\tSerious\trare\tevents\tinclude\tStevens-Johnson\tsyndrome\tand\tliver\t\nfailure.\tConcomitant\tuse\twith\tother\tmedications\tthat\tincrease\tserotonin\tconcentra-\ntion\t(including\ttramadol)\tincreases\trisk\tof\tserotonin\tsyndrome.\n•\tHyaluronic\t acid\t (sodium\t hyaluronate)\t injections\t have\t limited\t benefit\t for\t patients\t\nwith\tknee\tOA\tand\thave\tnot\tbeen\tshown\tto\tbenefit\tpatients\twith\thip\tOA.\tInjections\t\nare\twell\ttolerated,\tbut\tacute\tjoint\tswelling,\teffusion,\tand\tstiffness,\tas\twell\tas\tlocal\tskin\t\nreactions\t(eg,\trash,\tecchymoses,\tor\tpruritus)\thave\tbeen\treported.\tSix\tintra-articular\t\npreparations\tand\tregimens\tare\tavailable\tfor\tOA\tknee\tpain:\n✓\tSodium hyaluronate 20 mg/2 mL\t(Hyalgan)\tonce\tweekly\tfor\tfive\tinjections\n✓\tSodium hyaluronate 20 mg/2 mL\t(Euflexxa)\tonce\tweekly\tfor\tthree\tinjections\n✓\tSodium hyaluronate 25 mg/2.5 mL\t(Supartz)\tonce\tweekly\tfor\tfive\tinjections\n✓\tHylan polymers 16 mg/2 mL\t(Synvisc)\tonce\tweekly\tfor\tthree\tinjections\n✓\t\tHylan polymers 48 mg/6 mL \t (Synvisc-One)\t single\t injection\t (with\t efficacy\t for\t\nup\tto\t26\tweeks)\n✓\tHyaluronan 30 mg/2 mL\t(Orthovisc)\tonce\tweekly\tfor\tthree\tinjections\n•\tGlucosamine\tadverse\teffects\tare\tmild\tand\tinclude\tflatulence,\tbloating,\tand\tabdominal\t\ncramps;\t do\t not\t use\t in\t patients\t with\t shellfish\t allergies.\t The\t most\t common\t adverse\t\neffect\tof\tchondroitin\tis\tnausea.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tT o\tmonitor\tefficacy,\tassess\tbaseline\tpain\twith\ta\tvisual\tanalog\tscale,\tand\tassess\trange\t\nof\tmotion\tfor\taffected\tjoints\twith\tflexion,\textension,\tabduction,\tor\tadduction.\n•\tDepending\ton\tthe\tjoint(s)\taffected,\tmeasurement\tof\tgrip\tstrength\tand\t50-ft\twalking\t\ntime\tcan\thelp\tassess\thand\tand\thip/knee\tOA,\trespectively.\n•\tBaseline\t radiographs\tcan\t document\textent\tof\t joint\tinvolvement\tand\t follow\tdisease\t\nprogression\twith\ttherapy.\n•\tOther\t measures\t include\t the\t clinician’ s\t global\tassessment\t based\ton\t patient’ s\t history\t\nof\t activities\t and\t limitations\t caused\t by\t OA,\t the\t W estern\t Ontario\t and\t McMaster\t\nUniversities\tArthrosis\tIndex,\tStanford\tHealth\tAssessment\tQuestionnaire,\tand\tdocu-\nmentation\tof\tanalgesic\tor\tNSAID\tuse.\n•\tAsk\t patients\t about\t adverse\t effects\t from\t medications.\t Monitor\t for\t signs\t of\t drug-\nrelated\teffects,\tsuch\tas\tskin\trash,\theadaches,\tdrowsiness,\tweight\tgain,\tor\thypertension\t\nfrom\tNSAIDs.\n•\tObtain\tbaseline\tserum\tcreatinine,\thematology\tprofile,\tand\tserum\ttransaminases\twith\t\nrepeat\tlevels\tat\t6-\tto\t12-month\tintervals\tto\tidentify\tspecific\ttoxicities\tto\tthe\tkidney,\t\nliver,\tGI\ttract,\tor\tbone\tmarrow.\nSee Chapter 71, Osteoarthritis, authored by Lucinda M. Buys and Mary Elizabeth Elliott, \nfor a more detailed discussion of this topic.",
    "word_count": 524,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0046",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 46,
    "text": "16\n•\tOsteoporosis\t is\t a\t bone\t disorder\t characterized\t by\t low\t bone\t density,\t impaired\t bone\t\narchitecture,\tand\tcompromised\tbone\tstrength\tpredisposing\tto\tfracture.\nPATHOPHYSIOLOGY\n•\tBone\tloss\toccurs\twhen\tresorption\texceeds\tformation,\tusually\tfrom\thigh\tbone\tturn-\nover\t when\t number\t and/or\t depth\t of\t bone\t resorption\t sites\t greatly\t exceed\t ability\t of\t\nosteoblasts\tto\tform\tnew\tbone.\n•\tBone\tmineral\tdensity\t(BMD)\tis\treduced\tand\tbone\tstructural\tintegrity\tis\timpaired\tdue\t\nto\tincreased\timmature\tbone\tthat\tis\tnot\tyet\tadequately\tmineralized.\n•\tMen\t and\t women\t begin\t to\t lose\t bone\t mass\t starting\t in\t the\t third\t or\t fourth\t decade\t\nbecause\tof\treduced\tbone\tformation.\tEstrogen\tdeficiency\tduring\tmenopause\tincreases\t\nosteoclast\t activity,\t increasing\t bone\t resorption\t more\t than\t formation.\t Men\t do\t not\t\nundergo\t a\t period\t of\t accelerated\tbone\t resorption\tsimilar\t to\t menopause.\tSecondary\t\ncauses\tand\taging\tare\tthe\tmost\tcommon\tcontributing\tfactors\tto\tmale\tosteoporosis.\n•\tAge-related\tosteoporosis\tresults\tfrom\thormone,\tcalcium,\tand\tvitamin\tD\tdeficiencies\t\nleading\tto\taccelerated\tbone\tturnover\tand\treduced\tosteoblast\tformation.\n•\tDrug-induced\t osteoporosis\t may\t result\t from\t systemic\t corticosteroids,\t thyroid\t hor-\nmone\t replacement,\t antiepileptic\t drugs\t (eg,\t phenytoin\t and\t phenobarbital),\t depot\t\nmedroxyprogesterone\tacetate,\tand\tother\tagents.\nCLINICAL PRESENTATION\n•\tMany\tpatients\tare\tunaware\tthat\tthey\thave\tosteoporosis\tand\tonly\tpresent\tafter\tfrac-\nture.\t Fractures\t can\t occur\t after\t bending,\t lifting,\t or\t falling\t or\t independent\t of\t any\t\nactivity.\n•\tThe\t most\t common\t fractures\t involve\t vertebrae,\t proximal\t femur,\t and\t distal\t radius\t\n(wrist\tor\tColles\tfracture).\tV ertebral\tfractures\tmay\tbe\tasymptomatic\tor\tpresent\twith\t\nmoderate\t to\t severe\t back\t pain\t that\t radiates\t down\t a\t leg.\t Pain\t usually\t subsides\t after\t\n2\t to\t 4\t weeks,\t but\t residual\t low-back\t pain\t may\t persist.\t Multiple\t vertebral\t fractures\t\ndecrease\theight\tand\tsometimes\tcurve\tthe\tspine\t(kyphosis\tor\tlordosis)\twith\tor\twithout\t\nsignificant\tback\tpain.\n•\tPatients\t with\t a\tnonvertebral\t fracture\t frequently\t present\t with\tsevere\t pain,\t swelling,\t\nand\treduced\tfunction\tand\tmobility\tat\tthe\tfracture\tsite.\nDIAGNOSIS\n•\tThe\tW orld\tHealth\tOrganization\t(WHO)\tfracture\tprediction\tmodel\tfor\ttreatment\trisk\t\nstratification\tuses\tthese\trisk\tfactors\tto\tpredict\tthe\tpercent\tprobability\tof\tfracture\tin\t\nthe\tnext\t10\tyears:\tage,\trace/ethnicity,\tsex,\tprevious\tfragility\tfracture,\tparent\thistory\tof\t\nhip\tfracture,\tbody\tmass\tindex,\tglucocorticoid\tuse,\tcurrent\tsmoking,\talcohol\t(three\tor\t\nmore\tdrinks\tper\tday),\trheumatoid\tarthritis,\tand\tselect\tsecondary\tcauses\twith\tfemoral\t\nneck\tBMD\tdata\toptional.\n•\tPhysical\texamination\tfindings:\tbone\tpain,\tpostural\tchanges\t(ie,\tkyphosis),\tand\tloss\t\nof\theight\t(>1.5\tin\t[3.8\tcm]).\n•\tLaboratory\ttesting:\tcomplete\tblood\tcount,\tcreatinine,\tblood\turea\tnitrogen,\tcalcium,\t\nphosphorus,\talkaline\tphosphatase,\talbumin,\tthyroid-stimulating\thormone,\tfree\ttes-\ntosterone,\t25-hydroxyvitamin\tD,\tand\t24-hour\turine\tconcentrations\tof\tcalcium\tand\t\nphosphorus.\n•\tMeasurement\tof\tcentral\t(hip\tand\tspine)\tBMD\twith\tdual-energy\tx-ray\tabsorptiometry\t\n(DXA)\t is\t the\t diagnostic\t standard.\t Measurement\t at\t peripheral\t sites\t (forearm,\t heel,\t\nand\tphalanges)\twith\tultrasound\tor\tDXA\tis\tused\tonly\tfor\tscreening\tand\tfor\tdetermin-\ning\tneed\tfor\tfurther\ttesting.\nOsteoporosis\n3\nC H A P T E R",
    "word_count": 468,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0047",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 47,
    "text": "17\nOsteoporosis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0048",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 48,
    "text": "17\nOsteoporosis     CHAPTER 3\n•\tA\t T-score\t compares\t the\t patient’ s\t measured\t BMD\t to\t the\t mean\t BMD\t of\t a\t healthy,\t\nyoung\t(20-\tto\t29-year-old),\tgender-matched,\twhite\treference\tpopulation.\tThe\tT-score\t\nis\tthe\tnumber\tof\tstandard\tdeviations\tfrom\tthe\tmean\tof\tthe\treference\tpopulation.\n•\tDiagnosis\tof\tosteoporosis\tis\tbased\ton\tlow-trauma\tfracture\tor\tcentral\thip\tand/or\tspine\t\nDXA\t using\tWHO\tT-score\t thresholds.\t Normal\tbone\tmass\t is\tT-score\t above\t −1,\tlow\t\nbone\tmass\t(osteopenia)\tis\tT-score\tbetween\t−1\tand\t−2.4,\tand\tosteoporosis\tis\tT-score\t\nat\tor\tbelow\t−2.5.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\tprimary\tgoal\tof\tosteoporosis\tcare\tis\tprevention.\tOptimizing\t\npeak\tbone\tmass\twhen\tyoung\treduces\tthe\tfuture\tincidence\tof\tosteoporosis.\tAfter\tlow\t\nbone\t mass\t or\t osteoporosis\t develops,\t the\t objective\t is\t to\t stabilize\t or\t improve\t bone\t\nmass\t and\t strength\t and\t prevent\t fractures.\t Goals\t in\t patients\t with\t osteoporotic\t frac-\ntures\t include\t reducing\t pain\t and\t deformity,\t improving\t function,\t reducing\t falls\t and\t\nfractures,\tand\timproving\tquality\tof\tlife.\n•\tFigure 3–1 \t provides\t an\t osteoporosis\t management\t algorithm\t for\t postmenopausal\t\nwomen\tand\tmen\tages\t50\tand\tolder.\nNONPHARMACOLOGIC THERAPY\n•\tAll\t individuals\t should\t have\t a\t balanced\t diet\t with\t adequate\t intake\t of\t calcium\t and\t\nvitamin D \t (Table 3–1 ).\t Achieving\t daily\t calcium\t requirements\t from\t calcium-\ncontaining\tfoods\tis\tpreferred.\n✓\t\tConsumers\tcan\tcalculate\tthe\tamount\tof\tcalcium\tin\ta\tfood\tserving\tby\tadding\ta\tzero\t\nto\tthe\tpercentage\tof\tthe\tdaily\tvalue\ton\tfood\tlabels.\tOne\tserving\tof\tmilk\t(8\toz\tor\t\n240\tmL)\thas\t30%\tof\tthe\tdaily\tvalue\tof\tcalcium;\tthis\tconverts\tto\t300\tmg\tof\tcalcium\t\nper\tserving.\n✓\t\tT o\tcalculate\tthe\tamount\tof\tvitamin\tD\tin\ta\tfood\tserving,\tmultiply\tthe\tpercent\tdaily\t\nvalue\tof\tvitamin\tD\tlisted\ton\tthe\tfood\tlabel\tby\t4.\tFor\texample,\t20%\tvitamin\tD\t=\t\n80\tunits.\n•\tAlcohol\t consumption\t should\t not\t exceed\t one\t drink\t per\t day\t for\t women\t and\t two\t\ndrinks\tper\tday\tfor\tmen.\n•\tIdeally,\tcaffeine\tintake\tshould\tbe\tlimited\tto\ttwo\tor\tfewer\tservings\tper\tday.\n•\tSmoking\t cessation\t helps\t optimize\t peak\t bone\t mass,\t minimize\t bone\t loss,\t and\t ulti-\nmately\treduce\tfracture\trisk.\n•\tW eight-bearing\t aerobic\t and\t strengthening\t exercises\t can\t decrease\t risk\t of\t falls\t and\t\nfractures\tby\timproving\tmuscle\tstrength,\tcoordination,\tbalance,\tand\tmobility.\nPHARMACOLOGIC THERAPY\nANTIRESORPTIVE THERAPY\nCalcium Supplementation\n•\tCalcium\tincreases\tBMD,\tbut\tits\teffects\tare\tless\tthan\tthose\tof\tother\ttherapies.\tFracture\t\nprevention\tis\tonly\tdocumented\twith\tconcomitant\tvitamin\tD\ttherapy;\tcalcium\tshould\t\nbe\t combined\t with\tvitamin\t D\t and\tosteoporosis\t medications\t when\t needed.\tBecause\t\nthe\t fraction\t of\t calcium\t absorbed\t decreases\t with\t increasing\t dose,\t maximum\t single\t\ndoses\tof\t600\tmg\tor\tless\tof\telemental\tcalcium\tare\trecommended.\n•\tCalcium carbonate\tis\tthe\tsalt\tof\tchoice\tbecause\tit\tcontains\tthe\thighest\tconcentration\t\nof\telemental\tcalcium\t(40%)\tand\tis\tleast\texpensive.\tIt\tshould\tbe\tingested\twith\tmeals\t\nto\tenhance\tabsorption\tin\tan\tacidic\tenvironment.\n•\tCalcium citrate\tabsorption\tis\tacid\tindependent\tand\tneed\tnot\tbe\ttaken\twith\tmeals.\tIt\t\nmay\thave\tfewer\tGI\tside\teffects\t(eg,\tflatulence)\tthan\tcalcium\tcarbonate.\n•\tTricalcium phosphate \t contains\t 38%\t calcium,\t but\t calcium-phosphate\t complexes\t\ncould\tlimit\toverall\tcalcium\tabsorption.\tIt\tmight\tbe\thelpful\tin\tpatients\twith\thypophos-\nphatemia\tthat\tcannot\tbe\tresolved\twith\tincreased\tdietary\tintake.",
    "word_count": 521,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0049",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 49,
    "text": "18\nSECTION 1     Bone and Joint Disorders\nNO\nYES\nOsteoporosis or high fracture risk\nT-score ≤ –2.5 at femoral neck\nor spine or T-score –1.1 to –2.4 at\nfemoral neck, total hip, or spine and a\nFRAX 10-year probability of hip\nfracture ≥3% or all major\nosteoporosis-related fractures ≥20%h\nPresence of a low trauma fracture (vertebrae or hip)\n•    Woman ≥65 years of age\n•    Man ≥70 years of age\n•    Postmenopausal woman <65 years of age or man 50 to 69 years old with clinical risk\n  factors for fracturesa\n•    Abnormal peripheral BMD test\n•    Radiographic evidence of low bone mass\n•    Medical conditions or medications known to increase the risk for bone loss and fracture\n ( eg, rheumatoid arthritis, glucocorticoids ≥3 months)\n•   Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D at least 800 to 1000 units daily\n• Medication therapy:d\n • First line: alendronate, risedronate,\n  zoledronic acid or denosumab\n • Alternate therapy: Ibandronate, raloxifene,e\n  or teriparatidef\n • Last line: intranasal calcitoning\n Obtain baseline central BMD testing for\n monitoring response to therapy.\n Re-evaluate BMD using central DXA in 1–2 years \nNormal BMD T-score ≥ –1.0\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n Re-evaluate BMD using central\n DXA in 5 years or as appropriate\nYES\nLow bone mass (osteopenia)\nT-score –1.1 to –2.4 at femoral neck\nor spine and a FRAX 10-year probability\nof hip fracture <3% or of all major\nosteoporosis-related fractures <20%h\nSend for central DXA testing\n•   Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n• Medication therapy to prevent further bone loss\n can be considered if risk factors exist\n Re-evaluate BMD using central\n DXA in ≥2 years or as appropriate\naMajor clinical risk factors for fracture:  current smoker, low body weight or body mass index, history of osteoporosis/low trauma fracture in a first-degree relative,\npersonal history of fracture as an adult (after age 50 years), excessive alcohol intake\nbBone-healthy lifestyle includes smoking cessation, limit alcohol intake, well-balanced diet with adequate calcium and vitamin D intakes, weight-bearing/resistance exercises, and fall prevention\ncDietary calcium preferred.",
    "word_count": 373,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0050",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 50,
    "text": "  Bone and Joint Disorders\nNO\nYES\nOsteoporosis or high fracture risk\nT-score ≤ –2.5 at femoral neck\nor spine or T-score –1.1 to –2.4 at\nfemoral neck, total hip, or spine and a\nFRAX 10-year probability of hip\nfracture ≥3% or all major\nosteoporosis-related fractures ≥20%h\nPresence of a low trauma fracture (vertebrae or hip)\n•    Woman ≥65 years of age\n•    Man ≥70 years of age\n•    Postmenopausal woman <65 years of age or man 50 to 69 years old with clinical risk\n  factors for fracturesa\n•    Abnormal peripheral BMD test\n•    Radiographic evidence of low bone mass\n•    Medical conditions or medications known to increase the risk for bone loss and fracture\n ( eg, rheumatoid arthritis, glucocorticoids ≥3 months)\n•   Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D at least 800 to 1000 units daily\n• Medication therapy:d\n • First line: alendronate, risedronate,\n  zoledronic acid or denosumab\n • Alternate therapy: Ibandronate, raloxifene,e\n  or teriparatidef\n • Last line: intranasal calcitoning\n Obtain baseline central BMD testing for\n monitoring response to therapy.\n Re-evaluate BMD using central DXA in 1–2 years \nNormal BMD T-score ≥ –1.0\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n Re-evaluate BMD using central\n DXA in 5 years or as appropriate\nYES\nLow bone mass (osteopenia)\nT-score –1.1 to –2.4 at femoral neck\nor spine and a FRAX 10-year probability\nof hip fracture <3% or of all major\nosteoporosis-related fractures <20%h\nSend for central DXA testing\n•   Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n• Medication therapy to prevent further bone loss\n can be considered if risk factors exist\n Re-evaluate BMD using central\n DXA in ≥2 years or as appropriate\naMajor clinical risk factors for fracture:  current smoker, low body weight or body mass index, history of osteoporosis/low trauma fracture in a first-degree relative,\npersonal history of fracture as an adult (after age 50 years), excessive alcohol intake\nbBone-healthy lifestyle includes smoking cessation, limit alcohol intake, well-balanced diet with adequate calcium and vitamin D intakes, weight-bearing/resistance exercises, and fall prevention\ncDietary calcium preferred. If diet is inadequate, supplement as necessary\ndSometimes men with hypogonadism also receive testosterone replacement; sometimes women with menopausal symptoms receive low dose hormone therapy for a short time\neRaloxifene can be a good option in women at high risk for breast cancer\nfTeriparatide can be considered a first-line option in patients with a very high risk of fracture (eg, T-score <–3.5 or multiple low trauma fractures) or intolerant to other medications\ngCalitonin is last-line due to limited fracture data and a recent concern over possible slight increased cancer risk.\nhWHO absolute fracture risk assessment tool (FRAX) for osteoporotic fracture risk estimations\n• Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n•  Vitamin D at least 800 to 1000 units daily\n•  Medication therapyd:\n  • First line: alendronate, risedronate, zoledronic acid\n or denosumab\n  • Alternate therapy: ibandronate raloxifene,e\n or teriparatidef\n  • Last line: intranasal calcitoning\n     \n     Obtain baseline central BMD testing for\n     monitoring response to therapy.\n  Re-evaluate BMD using central\n  DXA in 1–2 years\nFIGURE 3–1.",
    "word_count": 543,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0051",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 51,
    "text": "If diet is inadequate, supplement as necessary\ndSometimes men with hypogonadism also receive testosterone replacement; sometimes women with menopausal symptoms receive low dose hormone therapy for a short time\neRaloxifene can be a good option in women at high risk for breast cancer\nfTeriparatide can be considered a first-line option in patients with a very high risk of fracture (eg, T-score <–3.5 or multiple low trauma fractures) or intolerant to other medications\ngCalitonin is last-line due to limited fracture data and a recent concern over possible slight increased cancer risk.\nhWHO absolute fracture risk assessment tool (FRAX) for osteoporotic fracture risk estimations\n• Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n•  Vitamin D at least 800 to 1000 units daily\n•  Medication therapyd:\n  • First line: alendronate, risedronate, zoledronic acid\n or denosumab\n  • Alternate therapy: ibandronate raloxifene,e\n or teriparatidef\n  • Last line: intranasal calcitoning\n     \n     Obtain baseline central BMD testing for\n     monitoring response to therapy.\n  Re-evaluate BMD using central\n  DXA in 1–2 years\nFIGURE 3–1.  Algorithm for management of osteoporosis in postmenopausal women and men ages 50 and older. BMD, bone mineral density; DXA, \ndual-energy x-ray absorptiometry.",
    "word_count": 195,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0052",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 52,
    "text": "19\nOsteoporosis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0053",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 53,
    "text": "19\nOsteoporosis     CHAPTER 3\n•\tConstipation\tis\tthe\tmost\tcommon\tadverse\treaction;\ttreat\twith\tincreased\twater\tintake,\t\ndietary\tfiber\t(given\tseparately\tfrom\tcalcium),\tand\texercise.\tCalcium\tcarbonate\tcan\t\nsometimes\tcause\tflatulence\tor\tupset\tstomach.\tCalcium\tcauses\tkidney\tstones\trarely.\nVitamin D Supplementation\n•\tVitamin D\tsupplementation\tmaximizes\tintestinal\tcalcium\tabsorption\tand\tBMD;\tit\t\nmay\talso\treduce\tfractures\tand\tfalls.\n•\tSupplementation\tis\tusually\tprovided\twith\tdaily\tnonprescription\tcholecalciferol\t(vita-\nmin\t D3)\t products.\t Higher-dose\t prescription\t ergocalciferol\t (vitamin\t D2)\t regimens\t\ngiven\tweekly,\tmonthly,\tor\tquarterly\tmay\tbe\tused\tfor\treplacement\tand\tmaintenance\t\ntherapy.\n•\tThe\trecommended\tdietary\tallowances\tin\tTable 3–1\tshould\tbe\tachieved\tthrough\tfood\t\nand\tsupplementation\twith\ta\tgoal\tto\tmaintain\tthe\t25\t(OH)\tvitamin\tD\tconcentration\t\nat\t30\tng/mL\t(75\tnmol/L)\tor\thigher.\n•\tBecause\tthe\thalf-life\tof\tvitamin\tD\tis\tabout\t1\tmonth,\trecheck\tthe\tvitamin\tD\tconcentra-\ntion\tafter\tabout\t3\tmonths\tof\ttherapy.\nBisphosphonates\n•\tBisphosphonates\t(Table 3–2)\tinhibit\tbone\tresorption\tand\tbecome\tincorporated\tinto\t\nthe\tbones,\tgiving\tthem\tlong\tbiologic\thalf-lives\tof\tup\tto\t10\tyears.\n•\tOf\tthe\tantiresorptive\tagents\tavailable,\tbisphosphonates\tprovide\tsome\tof\tthe\thigher\t\nBMD\tincreases\tand\tfracture\trisk\treductions.\tFracture\treductions\tare\tdemonstrated\t\nas\tearly\tas\t6\tmonths.\n•\tBMD\tincreases\tare\tdose\tdependent\tand\tgreatest\tin\tthe\tfirst\t6\tto\t12\tmonths\tof\ttherapy.\t\nAfter\t discontinuation,\tthe\tincreased\tBMD\tis\tsustained\tfor\ta\tprolonged\tperiod\tthat\t\nvaries\tdepending\ton\tthe\tbisphosphonate\tused.\n•\tAlendronate, risedronate,\tand\tIV zoledronic acid\tare\tFood\tand\tDrug\tAdministration\t\n(FDA)–indicated\tfor\tpostmenopausal,\tmale,\tand\tglucocorticoid-induced\tosteoporo-\nsis.\tIV and oral ibandronate\tare\tindicated\tonly\tfor\tpostmenopausal\tosteoporosis.\n•\tBisphosphonates\t must\t be\t administered\t carefully\t to\t optimize\t clinical\t benefit\t and\t\nminimize\tadverse\tGI\teffects.\tEach\toral\ttablet\tshould\tbe\ttaken\tin\tthe\tmorning\twith\t\nat\t least\t 6\t oz\t of\t plain\t tap\t water\t (not\t coffee,\t juice,\t mineral\t water,\t or\t milk)\t at\t least\t\t\n30\t minutes\t (60\t minutes\t for\t oral\t ibandronate)\t before\t consuming\t any\t food,\t supple-\nment,\tor\tmedication.\tAn\texception\tis\tdelayed-release\trisedronate,\twhich\tis\tadminis-\ntered\timmediately\tafter\tbreakfast\twith\tat\tleast\t4\toz\tof\tplain\twater.\tThe\tpatient\tshould\t\n TABLE 3–1   Calcium and Vitamin D: Recommended Dietary Allowances and Upper Limits\nGroup and Ages Elemental Calcium \n(mg) \nVitamin D (units)a \nInfants\n Birth to 6 months 200–1000 400–1000\n 6–12 months 260–1500 400–1500\nChildren\n 1–3 years 700–2500 600–2500\n 4–8 years 1000–2500 600–3000\n 9–18 years 1300–3000 600–4000\nAdults\n 19–50 years 1000–2500 600–4000b\n 51–70 years (men)\n 51–70 years (women)\n >70 years\n1000–2000\n1200–2000\n1200–200\n600–4000b\n600–4000b\n800–4000b\naOther guidelines recommend intake to achieve a 25(OH) vitamin D concentration of >30 ng/mL [75 \nnmol/L], which is higher than the Institute of Medicine goal of >20 ng/mL [50 nmol/L].\nb2010 National Osteoporosis Foundation Guidelines recommend 400–800 units for adults younger \nthan 50 years and 800–1000 units for adults 50 years and older.",
    "word_count": 460,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "dcb90cee_0054",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 54,
    "text": "[Truncated PDF extraction: processed first 30 of 976 pages]",
    "word_count": 9,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 14595,
      "char_count": 79554
    }
  },
  {
    "chunk_id": "50556800_0000",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 0,
    "text": "Principles of Pharmacology - Study Guide\n\nPrinciples of Pharmacology - Study Guide \nEdited by Dr. Esam El-Fakahan y and Becky Merk ey, MEd\n\nPrinciples of Pharmacology - Study Guide by Edited by Dr. Esam El-Fakahany and Becky Merkey, MEd is licensed under a Creative \nCommons Attribution-NonCommercial 4.0 International License, except where otherwise noted.\n\nContents \n1. Introduction to Pharmacology 1 \n2. Introduction to Drug-Receptor Interactions and Pharmacodynamics 5 \n3. Factors Contributing to Drug Effect 9 \n4. Pharmacological Descriptors of Drug-Receptor Interactions 13 \n5. Drug Action vs. Drug Effect 15 \n6. Characteristics of Drug-Receptor Interactions: 17 \n7. Response to Excessive and Reduced Stimulation of Receptors: 19 \n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & Antagonists 21 \n9. Receptor Allosteric Modulators 29 \n10. Competitive Antagonist vs. Negative Allosteric Modulator 31 \n11. Types of Drug-Drug Interactions 33 \n12. Introduction to Signal Transduction 35 \n13. Enzyme-Linked Receptors 41 \n15. Nuclear Receptors 47 \n16. Receptor Regulation 57 \n17. Ion Channels 65 \n21. Agents and Actions of the Autonomic Nervous System: Parasympathetic Nervous System 75 \n22. Agents and Actions of the Autonomic Nervous System: Sympathetic Nervous System 79\n\n1. Introduction to Pharmacology \nPharmacology: the study of interaction of drugs with living systems. \nSub-Disciplines of Pharmacology \n• Pharmacodynamics: effects and mechanisms of drug action \n◦ Drug-Receptor Interactions \n◦ Dose-Response Relationships \n◦ Signal Transduction \n• Pharmacokinetics: movement of drug throughout the body including: \n◦ Absorption \n◦ Distribution \n◦ Metabolism \n◦ Excretion \n• Pharmacogenetics: genetic factors play a role in the following: \n◦ Rate of Drug Metabolism \n◦ Drug-Induced Toxicity \n◦ Drug-Induced Allergies \n1\n\nPharmacology and the Pharmacist \nKey Questions you should be asking as a Pharmacist: \n• Where is the molecular site of action? \n• What are the body function changes caused by a drug (pharmacodynamics)? \n• What is the relationship between the Dose vs. Effect? \n• How does a drug produce its effect? \n2   Principles of Pharmacology - Study Guide",
    "word_count": 315,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0001",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 1,
    "text": "• What is the fate of the drug once it enters the body (pharmacokinetics)? \n• What is the interplay between genetic makeup and drug response? \nExample: Beta 1 Blocker: Metoprolol Succinate (oral) \nDrug Action:  selective binding to cardiac muscle beta 1 adrener gic receptors that respond to \nnorepinephrine (at higher doses, also inhibits bronchial and vascular smooth muscle by acting on beta 2 \nadrenergic receptors) to inhibit the binding of norepinephrine. \nDrug Effect: reduced inotropic effect (contractility) and chronotropic effect (heart rate) \nFate of the Drug (pharmacokinetics): 12% protein binding and distribution 5.6 L/kg: hepatic metabolism \n(CYP2D6 mainly): <5% renal excretion: t1/23-7 hours \n1. Introduction to Pharmacology   3\n\n2. Introduction to Drug-Receptor Interactions and Pharmacodynamics \nReceptors: protein molecules including enzymes, transporters and ion channels where a ligand (specific \nendogenous neurotransmitter/hormone or an external pharmacological agent (drug)) binds to, resulting in a \ncellular response. \n• Unique Exception: Orphan Receptors are receptors for which the ligand remains unknown. \n• Reminder: Ligand is an ion or molecule that forms a complex with a biomolecule to serve a specific \nbiological purpose \nExamples of Endogenous Ligands: \n◦ Neurotransmitters[NT]: chemical messengers signaling across a synaptic cleft \n▪ Acetylcholine [Ach] \n▪ Epinephrine [EPI] \n▪ Norepinephrine [NE] \n5\n\n◦ Hormones (peptide): secreted from neuroendocrine cells into the blood to signal at distant \ncells and tissues. \n▪ Aldosterone \n▪ Insulin \n▪ Nerve growth factor [NGF] \n▪ Thyroid hormone [TH] \n6   Principles of Pharmacology - Study Guide\n\n• Insulin is synthesized and released by pancreatic beta cells. It is transported through the blood to a \nvariety of cells to stimulate those cells to express glucose transporters allowing those cells to bring \nglucose into the cell for energy utilization. \nDRUG: A chemical agent that selectively interacts with specific tar get molecules (i.e. receptors) to alter their \nspecific physiological functions. \n• Agonist: drug that activates receptors to result in either stimulation or inhibition of the function of \nvarious types of cells and organs. \n• Antagonist: drug that prevents receptor activation by agonists. \n2. Introduction to Drug-Receptor Interactions and Pharmacodynamics   7\n\nDrug-Receptor Binding:  drugs bind to their respective receptor in a variety of ways depending on their \ncharacteristics. \n• Ionic interaction: cation & anion \n• Hydrogen bonding \n• Lipophilic interaction \n• Covalent bond: irreversible \n8   Principles of Pharmacology - Study Guide",
    "word_count": 378,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0002",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 2,
    "text": "3. Factors Contributing to Drug Effect \nThe Effect a Drug may have is Dependent on a Variety of Factors: \n1. Drug dosage: effect of drug increases with increased amount of drug up to the POINT OF \nRECEPTOR SATURATION \n2. Number of Receptors: receptors may be differentially expressed in one tissue to the next and, \ntherefore, mediate different levels of biological responses. \n◦ Example: Beta-1 receptors are most concentrated in the heart; therefore, beta-1 agonists \nproduce the greatest effects in the heart. Beta-2 receptors are most expressed in the \nbronchioles of the lungs and the arteries of skeletal muscle; therefore, beta-2 agonists \nproduce the greatest effects in these tissues and organs. \n3. Disease states: disease states can effect drug pharmacology \n◦ Example: pharmacokinetics of a drug change dramatically in a patient with chronic kidney \ndisease \n▪ Digoxin’s volume of distribution decreases when one has chronic kidney disease \n[CKD]. Clearance also decreases causing digoxin’s half-life to increase, meaning \nthat patient with CKD actually needs a lower dose than a patient with normal \nfunctioning kidney to achieve safe and effective digoxin levels. \n4. Drug Efficacy/Intrinsic activity: ability to activate or block a receptor: maximum effect a drug can \nproduce regardless of the dose \n9\n\n5. Drug Potency/Affinity: rate of drug-receptor binding and drug-receptor release: amount of drug \nneeded to produce a particular effect: drug affinity for receptor: \nSee below: the more potent the drug the quicker it binds its receptor (forward rate) and the slower it \nreleases from its receptor (reverse rate). \nEfficacy vs Potency: As drug efficacy increases, so does the maximal biological response it can produce. Efficacy \ncannot be changed by increasing the dose beyond that which elicits a maximal response, since it is an inherent \ncharacteristic of the drug. While potency is also an intrinsic property of a given drug, ef fects of the drug may \nbe increased by using higher doses because potency refers to the rate of drug-receptor binding and dissociation \nwhereas efficacy refers to the resultant biological response. \nEFFICACY of a drug is therefore more important clinically than \nPOTENCY since one could manipulate the drug dose to produce the desirable response in case of a drug with \nlow potency but a drug with low efficacy could not be manipulated in the same way. \n10   Principles of Pharmacology - Study Guide",
    "word_count": 383,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0003",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 3,
    "text": "Spare Receptors: often times occupation of only a fraction of receptors is necessary for obtaining a maximal \nresponse. In this case the remaining unbound receptors are known as spare receptors. This means that there can \nbe a reduction in receptors (up to a limit!!!) without a corresponding decrease in the maximal response. \n3. Factors Contributing to Drug Effect   11\n\n12   Principles of Pharmacology - Study Guide\n\n4. Pharmacological Descriptors of Drug-Receptor Interactions \nPharmacological Descriptors of Drug-Receptor Interactions  are used to describe and compare potency of \ndrugs \n• KD [equilibrium dissociation constant]: indicates drug concentration at which 50% of the receptors \nare occupied by the drug \nFYI: This is constant for a given drug-receptor system \n• Bmax [maximal specific binding]: represents the total number of receptors present in a cell or tissue \nReminder: a drug does not have to bind all available receptors in order to achieve the maximal effect \n(see spare receptors) \n13\n\n5. Drug Action vs. Drug Effect \nDrug Action:  drug-receptor interaction that results in a change in the tertiary structure of the receptor \n(conformational change) by agonists \n• See right: Norepinephrine [NE] acts as an agonist, activating its receptor to initiate a cascade of \ncellular events. \nDrug/Pharmacological Effect: specific changes in physiological function as a result of  drug interaction with a \nparticular receptor. \n• See right: the drug-receptor interaction leads to a cascade of events ultimately causing the heart to \ncontract. \n15\n\n16   Principles of Pharmacology - Study Guide",
    "word_count": 241,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0004",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 4,
    "text": "6. Characteristics of Drug-Receptor Interactions: \n1. Follow Mass-Action Law: rate of reaction is DIRECTLY proportional to the concentration of the \nreactants, however, there is a limit. This limit is called the point of saturation \n◦ There are only so many receptors on each cell to which a drug can bind. Point of saturation \nrefers to the point at which every receptor is bound. \n2. Selectivity: every drug has a preferred receptor; however, it may bind to others with the same or \nlesser affinity than its preferred receptor. Side effects of drugs are a direct result of low selectivity \nbecause one drug can bind multiple receptors producing undesired biological responses. \n◦ Not to be confused with “specificity” meaning drug can only bind to one type of receptor, \nregardless of the drug dose: drugs that are “specific” are unheard of at this point \n3. Response is Proportional to Drug Dose [Concentration] up to the point of saturation \n4. Binding Changes the Receptor: when a drug binds a receptor it results in one of two changes as \noutlined below: \nAGONIST: results in an active receptor conformation to produce desired biological effect, \ni.e. intracellular signaling or changes in organ function \n17\n\nANTAGONIST: a simple occupancy by the antagonist of the receptor to hinder access of an agonist \nto its binding site on the receptor, therefore, obliterating the response to the agonist. \n18   Principles of Pharmacology - Study Guide",
    "word_count": 234,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0005",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 5,
    "text": "7. Response to Excessive and Reduced Stimulation of Receptors: \nExcessive Receptor Activation can result in desensitization or down regulation. \nDesensitization: receptor becomes less responsive when exposed to a high concentration of an agonist drug for a \nlong duration (several minutes). \nWhat is an example of receptor desensitization? \nUnder normal physiological conditions acetylcholine stimulates nicotinic acetylcholine receptors on skeletal \nmuscle to open an ion channel that allows calcium influx to cause muscle contraction. Acetylcholine is hydrolyzed \nrapidly by acetylcholinesterase; the channel closes and is ready to be opened again upon the arrival of new \nacetylcholine molecules. Pharmacological inhibitors of acetylcholine esterase cause accumulation of high \nconcentrations of acetylcholine in the synaptic cleft. The ion channel on the receptor becomes insensitive to \nacetylcholine in attempt to protect the muscle from being overly activated. \nDown Regulation: the number of receptors decreases (by proteolysis) upon exposure to a high concentration of \nagonist for a very long time (hours), making the cell less responsive to the same agonist or others that work at the \nsame receptor. \nWhat is an example of downregulation? \n19\n\nType 2 Diabetes: chronic increased levels of glucose leads to increased production of insulin. Over time, insulin \nreceptors downregulate making the individual less sensitive to insulin. \nReduced Receptor stimulation: can result in receptor supersensitivity and upregulation. \nSupersensitivity and Upregulation: occurs when a cell is deprived of its natural ligand for a long time, resulting \nin increased receptor expression over time and making the cell more sensitive to its ligand \nWhat is an example of supersensitivity? \nReserpine depletes stores of catecholamines (e.g. norepinephrine) in neurons. Catecholamine receptors \ncompensate by becoming more abundant and therefore more responsive to exogenous catecholamine-like drugs. \n20   Principles of Pharmacology - Study Guide\n\n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & \nAntagonists \nAgonists: tend to be smaller molecules that effect activation of receptors. \nNote: This may result in stimulation or inhibition of cell and organ function \nFull agonists: produces maximal biological response \n• Has maximal POSITIVE INTRINSIC activity (EFFICACY) \nPartial agonists: produces partial maximal biological response as compared to full agonist \n• has lower POSITIVE INTRINSIC activity \n• may COMPETITIVELY INHIBIT full agonist preventing maximal biological response \n◦ If the partial agonist is bound to the receptor, the full agonist cannot bind \n• may have higher, lower or the same affinity (potency) for the receptor as the full agonist \n21",
    "word_count": 394,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0006",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 6,
    "text": "Why use a partial agonist? Full agonist may cause too much activation resulting in toxicity or receptor \nadaptation on prolonged use (desensitization, downregulation). The lower ef ficacy of partial agonists \nminimizes these complications. \nInverse agonists:  produces opposite biological response to that of the endogenous agonist/\nneurotransmitter \n• has NEGATIVE INTRINSIC activity (EFFICACY) \nExample: GABAA receptor: agonists (benzodiazepines) produce a sedative effect whereas inverse \nagonists (i.e. Rho15-4513 — originally designed as alcohol antidote) produce anxiety-like effects. \nAntagonists: tend to be larger molecules producing INHIBITORY effect. \n• there are antagonists that act at the receptor, also known as receptor antagonists, \n22   Principles of Pharmacology - Study Guide\n\n**Antagonists DO NOT  have INTRINSIC ACTIVITY (EFFICACY) : reminder: antagonist simply \nblock the agonist from binding. Furthermore, keep in mind that just because antagonists do not have \nintrinsic activity does not mean they do not have physiological consequences. \nExample: While the beta-1 antagonist DOES NOT  have INTRINSIC activity on its own, it still \nhas pharmacological ef fects in vivo. Under normal circumstances, when a person is exercising \nnorepinephrine is released binds to beta-1 receptors resulting in increased cardiac inotropy \n(contractility) as well as increased chronotropy (heart rate) to accommodate the increased demand \nfor oxygen. If an individual were using a beta-1 antagonist (a.k.a. beta blocker), it would prevent \nnorepinephrine from binding to beta-1 receptors thus causing reduced contractility and lower heart \nrate compared to someone who is not using a beta-1 antagonist. Labetalol is an example of a beta-1 \nantagonist used in individuals who have angina (chest pain) associated with increased heart rate. This \ndrug enables them to exercise, while maintaining a lower heart rate so as to avoid chest pain. \nCompetitive Antagonist/Inhibitor: REVERSIBLE or SURMMOUNTABLE \n◦ Binds to a receptor at the same site as an endogenous or pharmacological agonist, blocking \nagonist binding and therefore receptor activation. \n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & Antagonists   23",
    "word_count": 316,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "50556800_0007",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 7,
    "text": "• Antagonism is reversed by increasing the amount/dose of agonist (surmountable). While competitive \nantagonists do not affect agonist efficacy (maximal response), they do decrease AFFINITY and \nPOTENCY. Thus, a normal maximal response to the agonist may be attained in the presence of a \ncompetitive antagonist, albeit at higher agonist concentrations. Thus, agonist dose-response curve is \ntherefore SHIFTED TO THE RIGHT (more agonist needed to produce the same response) in the \npresence of a competitive antagonist (REFER TO GRAPH). \nIn this graph: \n◦ A: agonist \n◦ A + B: agonist + competitive antagonist \n24   Principles of Pharmacology - Study Guide\n\n[Truncated PDF extraction: processed first 30 of 87 pages]",
    "word_count": 108,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 2369,
      "char_count": 16099
    }
  },
  {
    "chunk_id": "1500f74c_0000",
    "doc_id": "1500f74c",
    "filename": "projectPlan.md",
    "source_folder": "docx",
    "file_type": ".md",
    "title": "HealthDose Project Plan",
    "drug_name": "Projectplan",
    "chunk_index": 0,
    "text": "HealthDose Project Plan\nPhase 1: Project Setup & Foundation\n\n<!-- • Initialize monorepo (PNPM Workspaces + Turborepo). -->\n<!-- • Set up React (Vite) frontend with Tailwind CSS and shadcn/ui. -->\n<!-- • Configure Firebase (Auth, Firestore, Storage). -->\n<!-- • Implement authentication system (patient, pharmacist, clinician roles). -->\n<!-- • Set up Google Cloud Functions (Node.js + TypeScript strict mode). -->\n\n• Configure CI/CD pipeline.\n• Basic UI scaffolding and layout structure.\nMilestone 1\n• User authentication working, architecture finalized, base UI ready.  \nPhase 2: Core Database & API Implementation\n\n<!-- • Design Firestore schema (Users, Medications, Interactions, Advice). #Martha -->\n\n<!-- • Populate medication database. #Lemmy -->\n\n<!-- • Implement tRPC API layer.  -->\n\n<!-- • Create medication search functionality. #Martha -->\n\n<!-- • Build drug interaction checker.#Lemmy -->\n\n<!-- • Add role-based access control (RBAC). -->\n\nMilestone 2\n• Medication search and interaction checker functional with role restrictions.\nPhase 3: RAG Engine Integration\n\n<!-- • Set up Vertex AI embedding pipeline. -->\n\n<!-- • Chunk and embed authoritative medical documents. -->\n\n• Configure Vector Database.\n• Integrate Gemini API for grounded generation.\n\n<!-- • Build backend RAG orchestration logic. -->\n\n• Display retrieved sources with AI responses.\nMilestone 3\n• End-to-end RAG pipeline operational with grounded responses.\nPhase 4: Safety, Compliance & UX Enhancements\n• Implement medical disclaimers and policies.\n• Add AI response feedback system.\n• Improve UI/UX and accessibility.\n• Add query history tracking.\n• Implement rate limiting and security hardening.\nMilestone 4\n• Application meets safety standards with stable UX and audit tracking.\nPhase 5: Testing & Optimization (Weeks 9–10)\n• Unit testing with Vitest.\n• Component testing with Testing Library.\n• End-to-end testing with Playwright.\n• Performance optimization and caching.\n• Security testing and validation.\n• Final production deployment.\nMilestone 5\n• Production-ready HealthDose platform deployed with full testing coverage.",
    "word_count": 307,
    "metadata": {
      "doc_id": "1500f74c",
      "filename": "projectPlan.md",
      "source_folder": "docx",
      "file_type": ".md",
      "title": "HealthDose Project Plan",
      "drug_name": "Projectplan",
      "source": "medical_document",
      "word_count": 307,
      "char_count": 2111
    }
  },
  {
    "chunk_id": "049ae0cd_0000",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 0,
    "text": "Lecture Notes: Retrieval-Augmented Generation \n(RAG) \n1. What is RAG? \nDefinition \nRetrieval-Augmented Generation (RAG) is the process of enhancing and optimizing the output of a large language model \n(LLM) by providing it with additional context retrieved from external data sources, ensuring more accurate, relevant, and \ngrounded responses. \nWhy Do We Need RAG? \nStandard LLMs are trained on a massive, but static, dataset. This leads to two major limitations: \n1. Stale Knowledge: The model has no information about anything that happened after its training data was collected. \n2. Hallucinations: The model can confidently \"make up\" facts or source citations that are plausible-sounding but \nincorrect. \n3. Lack of Specificity: The model has no access to private, proprietary, or domain-specific information (e.g., your \ncompany's internal policies, a user's personal documents, or real-time financial data). \nRAG solves this by connecting the LLM to a live, external knowledge source and \"grounding\" its answers in facts. \n2. The Core RAG Workflow \nAt its core, a RAG system performs three steps in response to a user's prompt: \n1. Retrieve: The user's prompt (e.g., \"What is our company's policy on remote work?\") is transformed into a query. \nThe system searches an external data source (the \"corpus\") for relevant information. \n2. Augment: The relevant information (e.g., the text from the \"Remote Work Policy.pdf\" document) is retrieved and \ncombined with the original prompt. This new, \"augmented\" prompt now contains both the user's question and the \nfactual context. \n3. Generate: This augmented prompt is fed to the LLM. The LLM is instructed to generate an answer based only on \nthe provided context. This forces the model to stick to the facts, effectively using it as a reasoning and \nsummarization engine rather than a knowledge recall engine. \n3. Methods of Retrieving External Information \nThe \"retrieval\" step is what makes RAG powerful. This external information can come from several sources. \nA. The RAG Corpus (The Knowledge Base) \nThis is the most common method. The corpus is the private, curated set of documents that you want the LLM to have \naccess to. \n● What is a Corpus? \nA corpus is a large, organized collection of text and data used as the \"knowledge library\" for the RAG system. It is \nthe \"ground truth\" that the LLM will consult. \n● Role in RAG: \nThe corpus serves as the long-term memory for the LLM.",
    "word_count": 386,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0001",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 1,
    "text": "\n● Role in RAG: \nThe corpus serves as the long-term memory for the LLM. Instead of retraining the entire model (which is slow and \nexpensive), you simply add new information to the corpus (e.g., add a new policy PDF). \n● Composition (How it's built):",
    "word_count": 44,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0002",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 2,
    "text": "A RAG corpus is not just a folder of files. It's a highly optimized, searchable index, typically built using a Vector \nDatabase. \n1. Ingestion: You load your raw data (e.g., PDFs, .txt files, Markdown, database entries, scraped web pages). \n2. Chunking: The documents are broken down into smaller, manageable \"chunks\" (e.g., paragraphs or sentences). \nThis is critical because you can't fit an entire 100-page document into the LLM's context window. \n3. Embedding: Each chunk is passed through an embedding model, which converts the text into a numerical \nrepresentation (a \"vector\"). This vector captures the semantic meaning of the text. \n4. Indexing: These vectors are stored in a Vector Database. This database is optimized to find vectors (and their \ncorresponding text chunks) that are \"semantically similar\" to the user's query vector. \nB. Web Scraping \nThis is a method for building a corpus by pulling data directly from the public web. \n● How it Works: \nWeb scraping is an automated process that fetches web pages and extracts specific data from them. A \"scraper\" bot \nvisits a URL, downloads the HTML, and then parses that HTML to pull out the desired text (e.g., blog post content, \nproduct descriptions, news articles). \n● Using Python for RAG: \nPython is the most common language for this. The workflow for building a RAG corpus from scraped data often \nlooks like this: \n1. Fetch: Use libraries like requests to download the web page. \n2. Parse: Use libraries like BeautifulSoup or Scrapy to navigate the HTML and extract the main text content, \nstripping away ads, navigation bars, and footers. \n3. Clean: Convert the extracted content into clean text or Markdown. \n4. Ingest: Feed this clean text into your RAG corpus pipeline (chunking, embedding, indexing) as described in \nsection 3A. \n5. Frameworks like LlamaIndex and LangChain have built-in \"Web Readers\" (ScrapflyReader, RAGScraper) that \ncan simplify this process into a few lines of code. \nC. APIs (Application Programming Interfaces) \nThis method is used to retrieve highly dynamic, real-time, or structured data. \n● Role in RAG: \nInstead of just searching a static database, the RAG system can be given \"tools,\" and one of those tools can be an \nAPI. This is essential when an answer depends on live data.",
    "word_count": 367,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0003",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 3,
    "text": "This is essential when an answer depends on live data. \n● How APIs Contribute: \n○ Free & Open Data Sources: Imagine a user asks, \"What's the weather in San Francisco and what's the top \nnews story about AI?\" A RAG system can be configured to: \n1. Parse the prompt into two sub-questions. \n2. Call a free Weather API for the San Francisco data. \n3. Call a free News API (like GNews) for the AI story. \n4. Combine both API responses (which are usually in a structured JSON format) into the \"context.\" \n5. Feed this context to the LLM to generate a single, natural-language answer. \n○ Internal/Proprietary APIs: A chatbot for an e-commerce store could use an internal API to check a user's \n\"order status\" or \"product availability\" from the company's live database. \n4. Real-World Use Cases \nRAG is not theoretical; it's already powering many applications you use. \n● Customer Support Chatbots (e.g., Shopify, DoorDash): When you ask a chatbot a question, it retrieves",
    "word_count": 163,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0004",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 4,
    "text": "information from the company's actual help center articles, product manuals, and internal FAQs to give you a \ncorrect, specific answer instead of a generic guess. \n● Healthcare (e.g., IBM Watson Health): A RAG system can assist doctors by taking a patient's symptoms (the \nprompt) and retrieving the most relevant, up-to-date research papers, clinical trial data, and treatment guidelines (the \ncorpus) to support a diagnosis. \n● Finance (e.g., Bloomberg): An analyst can ask, \"Summarize the key risks from Apple's latest quarterly earnings \nreport.\" The RAG system retrieves the actual 10-Q report (which was just released) and provides it to the LLM for \nsummarization, ensuring the answer is based on real-time, factual data. \n● Internal Knowledge Management (e.g., Assembly, Bell): Employees at a large company can use an internal \"Ask \nHR\" bot. This bot uses RAG to search all internal documents (employee handbooks, policy PDFs, intranet sites) to \nanswer questions like \"How do I submit an expense report?\" \n5. Building a RAG System with Vertex AI (Google Cloud) \nGoogle Cloud provides a powerful, managed platform to build and scale RAG systems using Vertex AI. \nKey Components \nVertex AI simplifies the RAG process by integrating all the necessary components: \n1. Vertex AI RAG Engine: This is the overarching service that manages the entire workflow, from data ingestion to \ngeneration. \n2. Data Ingestion & Connectors: You don't have to build complex data pipelines. You can point Vertex AI to your \ndata sources, including: \n○ Google Cloud Storage (for PDFs, .txt, etc.) \n○ Google Drive \n○ Third-party sources like Jira, Slack, or Salesforce. \n3. RagCorpus: This is the Vertex AI-managed service that automatically handles the data processing. When you add a \ndocument, it automatically performs chunking and parsing. \n4. Vertex AI Vector Search: This is the underlying vector database that creates the embeddings and performs the \nultra-fast semantic search. \n5. Generative Models (Gemini): The retrieved context is automatically fed to a Google Gemini model for the final, \ngrounded answer generation. \nThe Vertex AI Workflow (Simplified) \nWhile the console provides a \"clicks-not-code\" interface, you can also build this system programmatically using the \nPython SDK. \n1. Initialize Vertex AI: Connect to the Vertex AI platform. \nimport vertexai \nvertexai.init(project=\"your-project-id\", location=\"us-central1\") \n \n2. Create a Corpus: Create a RagCorpus to hold your data. \nfrom vertexai.preview import rag \nrag_corpus = rag.create_corpus(display_name=\"my-company-corpus\") \n \n3. Import Files: Upload your files (e.g., from a Google Cloud Storage bucket) into the corpus.",
    "word_count": 396,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0005",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 5,
    "text": "Import Files: Upload your files (e.g., from a Google Cloud Storage bucket) into the corpus. Vertex AI handles the \nchunking and embedding automatically. \nrag.import_files( \n    rag_corpus.name, \n    [\"gs://my-bucket/my-policy-doc.pdf\"],",
    "word_count": 26,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0006",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 6,
    "text": "chunk_size=1024 \n) \n \n4. Set up the RAG Tool: Create a RAG retrieval \"tool\" that the LLM can use. \nfrom vertexai.preview.generative_models import GenerativeModel, Tool \n \nrag_retrieval_tool = Tool.from_retrieval( \n    rag.Retrieval(source=rag.VertexRagStore(rag_corpora=[rag_corpus.name])) \n) \n \n5. Generate a Grounded Answer: Initialize a Gemini model and give it the RAG tool. Now, when you ask a question, \nthe model will automatically use the tool to find context from your corpus before answering. \nmodel = GenerativeModel( \n    \"gemini-1.5-flash-001\", \n    tools=[rag_retrieval_tool] \n) \n \nprompt = \"What is the company policy on remote work?\" \nresponse = model.generate_content(prompt) \n \nprint(response.text)  \n# This output will be grounded in the \"my-policy-doc.pdf\"",
    "word_count": 93,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  }
]
